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SUMMARY 
Heart valve disease is an increasing clinical burden associated with high morbidity and 
mortality. Current, valve replacements have a number of risks, such as thrombogenicity 
and calcification. For pediatric patients, a significant issue is the lack of small implants 
capable of growing, resulting in several surgical interventions for valve refitting. Patient-
specific, tissue engineered heart valves (TEHVs) have the potential to address these issues 
through their self-repairing and remodeling capacity. The overall objective of this thesis 
was to develop a TEHV that functions under physiological aortic valve conditions and has 
the potential to repair and remodel over time. The central hypothesis is a TEHV can be 
created by mimicking the structural components of the valve leaflet layers using 3D 
bioprinting and incorporating valvular interstitial cell (VIC)-like cells to actively 
regenerate and remodel. First, we generated a potential suitable cell source of human iPSC-
derived mesenchymal stem cells (iMSCs) that mature into VIC-like cells. Next, we used 
3D printing and a combination of poly-ε-caprolactone (PCL) and gelatin methacrylate - 
polyethylene (glycol) diacrylate (GelMA/PEGDA) hydrogel to create a cell-laden 
multilayered leaflet that recapitulates the layers of the valve leaflet. Lastly, the PCL-
component of the valve leaflet was mounted onto a valve stent and feasibility studies were 
conducted using a left-ventricle flow simulator to evaluate the hemodynamic performance 
of the PCL-TEHV under aortic valve conditions. We demonstrated a cell source can be 
derived from autologous iPSCs, generated a multilayered leaflet scaffold using a 
combination of natural and synthetic biomaterials, and verified the feasibility of the leaflet 
under aortic flow conditions. These promising findings are the first steps to a pre-clinical 
TEHV with the ability to regenerate and remodel with the patient. 
1 
CHAPTER 1  INTRODUCTION 
 
 An estimated two to three million children live with heart disease, about 5% of 
whom have heart valve disease [4-6]. This is mainly due to congenital heart defects in 
industrialized countries and the persistence of rheumatic fever in underdeveloped regions 
[7-9]. Valve disease is treated by replacement or valve repair. In most cases valve repair is 
not possible, and valve implants have a number of risks, such as thrombogenicity and 
calcification. A significant issue for pediatric patients is the lack of small implants capable 
of growing, often requiring several surgical interventions for valve refitting [4, 10]. Tissue 
engineered heart valves (TEHVs) have the potential to address limitations with current 
implants through their self-repairing and remodeling capacity.  
 Despite advances in TEHVs, the challenge to develop a mechanically functional 
TEHV for long-term implantation remains. The mechanical strength of valves is attributed 
to the microstructure of the leaflet layers, valvular interstitial cells (VICs), and overall 
macrostructure of the valve design. Thus far, we have shown that we can generate a suitable 
cell source of human iPSC-derived mesenchymal stem cells (iMSCs) that mature into VIC-
like cells [11]. To develop a mechanically functional TEHV, we have recapitulated features 
of the valve leaflet layers using 3D bioprinting and conducted feasibility studies using a 
left-ventricle flow simulator. The overall goal is to develop a TEHV that functions under 
physiological aortic valve conditions and has the potential to repair and remodel over time. 
We hypothesize we can create a TEHV by mimicking the structural components of the 
valve leaflet layers using 3D bioprinting and incorporating VIC-like cells to actively 
regenerate and remodel its surrounding matrix under physiological flow conditions.  
  
2 
CHAPTER 2  SPECIFIC AIMS 
: To differentiate iPSCs into iVICs using both biochemical and mechanical cues.  
iPSCs will be differentiated into iMSCs using a modified (feeder-free) protocol [2] 
and then encapsulated in polyethylene (glycol) diacrylate (PEGDA) hydrogels of varying 
stiffness, grafted with adhesion and degradation peptides. We will determine the efficiency 
of the differentiation protocol using flow cytometry to stain for MSC surface markers 
CD90, CD44, CD105, CD29, CD73, αSMA, and CD45. VIC phenotype will be 
characterized by the expression of αSMA, vimentin, F-actin, and ECM production after 
1,7, 14, and 28 days and compared to native VICs. 
:  To develop a multilayered leaflet with remodeling potential that mimics the 
structural and mechanical properties of native heart valve leaflets.  
Two types of biomaterials, biodegradable poly-e-caprolactone (PCL) and a 
formulation of gelatin methacrylate (GelMA) and polyethylene diacrylate (PEGDA) will 
be used to generate a multilayered leaflet scaffold. These two biomaterials are hypothesized 
to enable us to incorporate cells into the leaflet scaffold in addition to replicating the leaflet 
layers because these biomaterials are compatible with 3D printing. Furthermore, since the 
geometry and design are key components for a functional TEHV, 3D bioprinting and 
molding will be the primary approach used. To generate a load-bearing layer mimicking 
the fibrosa, PCL scaffolds will be 3D printed with three different strand orientations to 
assess which scaffold can recapitulate the anisotropy and alignment of the collagen fibers 
found in native leaflets. The overall material properties of the scaffold and its ability to 
degrade over time will be assessed with uniaxial testing. The interaction of iMSCs with the 
PCL scaffold will be characterized by alamarBlue and immunostaining for aSMA and 
vimentin. To develop cell-laden ventricularis and spongiosa layers, a blend of GelMA and 
3 
PEGDA will be used, and the mechanical properties as well as the cell viability will be 
characterized. Both PCL and the GelMA/PEGDA hydrogel will be combined to generate 
a multilayered scaffold for testing under pulsatile shear stress conditions, and the VIC-like 
phenotype and collagen type I production will be assessed via immunostaining.  
: To generate a TEHV prototype and evaluate the hemodynamic profile using a 
pulsatile flow loop.  
The leaflet, composed of the PCL layer only, will be assembled onto a 3D printed 
valve ring of 19 mm outer diameter and inner diameter of 17 mm for initial prototyping. 
The assembled TEHV will be tested to assess the hemodynamics and performance of the 
valve using a pulsatile left-ventricular flow loop. Valve kinematics will be evaluated by 
the effective orifice area, mean and max transvalvular pressure gradient, regurgitation 
volume, and the leakage and closing volume.  These parameters will be compared to 











CHAPTER 3  LITERATURE REVIEW i 
 
Heart valve disease is a worldwide clinical burden resulting in high morbidity and 
mortality [13-15]. With a prevalence of 2.5%, heart valve disease can range from 
degeneration of valves, to congenital defects, to rheumatic fever depending on social and 
geographical location [16]. As life-expectancy increases in industrialized countries, age-
dependent degeneration is expected to triple the prevalence of heart valve disease by 2050 
[7]. Meanwhile, structural malformation of heart valves, known as congenital heart valve 
disease, occurs in 1 to 2% of live births worldwide [17]. In socioeconomically vulnerable 
populations, rheumatic fever is a source for heart valve disease in children and adults who 
develop streptococcal throat infection that is left untreated [8, 18]. Rheumatic heart valve 
disease results in valve damage and progression of heart failure.  
 
The main function of heart valves is to maintain unidirectional flow of blood 
throughout the heart, and it does so by passively opening and closing over 100,000 times 
per day [19]. In the heart, there are four valves: tricuspid, pulmonary, mitral, and aortic. 
Diseased valves can result in the back flow of blood and abnormal pressure gradients in 
heart chambers. The valves most prone to disease are the mitral and aortic valve in the left 
ventricle [20]. When these valves become diseased, there can be regurgitation or stenosis 
of the valve leaflets. Regurgitation or valve insufficiency is described as the leakage of a 
valve during diastole. This can be caused by abnormalities in the aortic root geometry or 
rupture of the papillary muscles in the aortic or mitral valve, respectively [20]. Valve 
stenosis is the narrowing or obstruction of the valve opening, often caused by degenerative 
remodeling or congenital malformation [18]. The most common form of valve disease is 
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aortic valve stenosis [16]. Thus, most of the biomaterial applications for heart valve tissue 
engineering in this literature review will focus on aortic valve tissue engineering.  
Currently, there are limited therapeutics to prevent valve degeneration. Thus, heart 
valve disease is treated through either valve repair or valve replacement, with the latter 
being the most common treatment. This is because diagnosis of valve disease occurs when 
the disease has progressed to a point where repair is not feasible. Valves can be replaced 
with mechanical or biological prostheses through invasive open-heart surgery or 
transcatheter delivery. While valve prostheses have increased patient lifespan, there are 
numerous limitations. Some of those include the inability to remodel and maintain the 
structure similar to native valves. This is especially a drawback for pediatric patients due 
to the valve’s incapacity to grow and remodel with somatic growth. As a result, a child in 
need of a valve replacement will likely undergo several resizing surgeries, underscoring 
the need for a “living valve” that can actively regenerate and remodel to minimize the need 
for multiple surgeries in pediatric patients and reduce the limitations of current implants 
for adults [21]. 
In this literature review, the current approaches for treating heart valve disease will 
be discussed, followed by the design considerations for heart valve tissue engineering, a 
summary of biomaterials, fabrication techniques, and emerging technologies used to meet 
TEHV design criteria. Evaluations of TEHVs in in vivo and in physiological conditions are 
important to determine whether design considerations have been met. Thus, a summary of 







The invention and implantation of prosthetic heart valves to treat patients with 
dysfunctional, diseased valves came about in the 1950s. This followed the development of 
several surgical techniques in the years prior, including cardiac catheterization, the 
cardiopulmonary bypass pump, and the discovery of heparin and dicumarol as 
anticoagulants [22]. Since then, a wide variety of valve prostheses have been developed 
throughout the years (Figure 1) and can be divided into three main categories: mechanical, 
biological, and transcatheter. The advantages and disadvantages for each type of valve 
prostheses are summarized in Table 1.   
Figure 1. The evolution of valve prostheses. The rapid development of heart valve 
prostheses began with the first implantation of Hufnagel's mechanical ball valve in the 
1950s. Since then, the field has expanded to include a variation of different mechanical 
valve designs, as well as biological valve implants. Today, different technologies exist 
to treat a wider variety of people previously unsuitable for valve replacement, such as 
transcatheter valve implantation. Valve images adapted with permission [2]. Copyright 
2003, Elsevier. Edwards SAPIEN valve adapted with permission [3]. Copyright 2016, 
the authors, published under the terms of CC‐BY 4.0 license. 
7 
Table 1. Advantages and Disadvantages of Valve Prostheses. 
 
 
Charles Hufnagel created the first heart valve prosthesis, a mechanical prosthesis 
consisting of a polymethyl methacrylate acrylic ball valve implanted into the descending 
aorta. This approach was far from ideal, as a common complaint was the noise from the 
valve opening and closing, which resembled the noise of a ticking time bomb. Albert Starr 
and Dwight Harken built upon Hufnagel’s idea to create a caged ball valve. Following the 
successful implantation of these valves into the mitral and aortic valve positions in 1960, 
several designs for the ball valve prosthesis were developed by Starr and M. Lowell 
Edwards in order to reduce their thrombogenicity [22]. The Starr-Edwards ball valve 
consisted of a silicone ball that moved forward into a cage to open and fell back into the 
Prosthesis Advantages Disadvantages Ref.  
Mechanical 
- Durable (20-30 years) 
- Lower reoperation 
rates 
- Requires life-long 
anticoagulation 
- Higher risk of hemorrhages 
and thromboembolism 








- Does not require 
anticoagulants 
- Low risk for major 
bleeding, stroke, and 
valve thrombosis 
- Less durable (10-15 years) 
- Risk of structural valve 
deterioration 
- Higher reoperation rates 
Transcatheter 
Biological 
- Treatment option for 
intermediate- to high-
risk patients 
- Reduced invasiveness 
and faster recovery 
- Early development stages 
- Long-term follow up is scarce 
- Prosthesis-patient mismatch 
- High risk for stroke 





sewer ring to close. Since their creation, over 200,000 ball valves have been implanted 
[29].  
In order to address problems associated with the Starr-Edwards ball valves, 
including turbulence and shear stress, Viking Bjork and Donald Shiley created the tilting 
disk valve in the late 1960s [22]. The Bjork-Shiley valve consisted of a single graphite 
tilting disk coated in pyrolite carbon, which was held in place by two metal struts. In the 
1970s, the original design was modified to a convexo-concave shape, but the new design 
was prone to fracture, often resulting in patient death [29]. Today, Bjork-Shiley valves are 
no longer manufactured, but other manufacturers, such as Medtronic-Hall and Aortech 
Ultracor, still produce tilting disk valves [29]. 
The most common mechanical valve design today is the bileaflet valve, created in 
1977 by St. Jude Medical [29]. Bileaflet valves consist of two pivoting semicircular leaflets 
that open completely, making them popular because of all mechanical valve designs 
available, they offer the least impedance to blood flow. Today, several manufacturers 
produce bileaflet valves, including St. Jude Medical, OnX, and Sorin, that differ in 
composition and design [30]. 
According to two large randomized studies, mechanical valve prostheses are 
recommended for more active patients under the age of 60, as these prostheses are durable 
with the potential to last over 20 years, and often do not require replacement surgeries [23-
25]. However, recipients of mechanical heart valves are at a higher risk for 
thromboembolism, and so they must remain on lifelong anticoagulation therapy, exposing 
them to higher risks of bleeding and hemorrhages associated with this therapy [25, 27]. 
The thrombogenicity of materials used in mechanical valves, high shear stress profile, and 
backflow of blood are reasons why patients with mechanical valves require lifelong 
anticoagulation therapy [26]. The high shear stress can cause damage to blood cells and 
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activate the blood clotting-pathways, resulting in thrombosis and potential risk of stroke. 
Mechanical valves are more susceptible to infections that are difficult to treat and 
oftentimes require replacement of the prosthesis [27]. For infants born with congenital 
valve defects, mechanical valves are not ideal, as they do not come in sizes small enough 
(16 mm to 29 mm in diameter) for newborns, and they fail to grow [31].  
 
To eliminate the need for anticoagulation treatment in patients who have undergone 
valve surgeries, biological materials were sought after to replace diseased valves. Since the 
late 1950s, many different types of biological valves have been created, ranging from 
valves coming from the patient’s own body (autografts and autologous valves), to valves 
from human donors (homografts), to valves from other animal species (xenografts).  
Valve prostheses fashioned from the patient’s own tissue arose shortly after the 
development of mechanical valves. In 1967, Donald Ross described a procedure in which 
a patient’s healthy pulmonary valve was excised and used to replace the diseased aortic 
valve [30]. Meanwhile, a valve prosthesis was placed in the pulmonary position. While 
technically complex, patients who have undergone the Ross procedure have better long-
term survival compared to alternatives [30]. This is due to its excellent hemodynamic 
profile, lack of anticoagulation therapy, and ability to grow and integrate with patient [31]. 
Around the same time, valve prostheses constructed by the surgeon’s hands using the 
patient’s own tissue were implanted, but due to the technically demanding nature of this 
procedure, it was eventually abandoned [29]. 
Homografts are valve prostheses donated from human cadavers, organ donors, or 
heart transplant patients, and are sterilized and preserved in preparation for implantation 
[29]. Similarly, xenografts are valve prostheses typically from porcine aortic valves or 
bovine pericardium, and these are often preserved with glutaraldehyde to stabilize collagen 
10 
structure and reduce antigenicity [32]. Since their production in 1965, xenografts have 
become the most frequently implanted biological valve [20]. Two common classes of 
xenografts include porcine aortic valves, such as the St. Jude Medical Epic and Medtronic 
Hancock, and bovine pericardial valves, such as the Edwards Perimount and Sorin 
Mitroflow [22].A xenograft currently coming into the market is the Edwards Inspiris 
Resilia, a bovine pericardial valve designed to better resist calcification. 
While biological heart valves eliminate the need for anticoagulation therapy, they 
are not as durable as mechanical heart valves. Patients must often undergo valve 
replacement surgery within 10 to 15 years, as biological valves degrade over time [33]. 
Thus, biological heart valves are often recommended for patients above 60 to 70 years of 
age [26]. For pediatric patients who desire to avoid anticoagulation therapy, biological 
heart valves are available, but they are not ideal, as younger patients have a higher rate of 
degradation and thus require biological valves to be replaced more often [32, 34]. 
 
In the past decade, a new category of heart valve prostheses has emerged. 
Transcatheter valve prostheses consist of tissue mounted on an expandable stent, and they 
are introduced into the body in a variety of ways, such as via the femoral artery, the aorta, 
or the subclavian artery. Today, many variations of transcatheter valves exist, including the 
Edwards SAPIEN, Medtronic CoreValve, and the St. Jude Medical Portico [30]. Currently, 
all transcatheter valves are composed of biological tissue as this is necessary for the leaflets 
to be crimped into a catheter. However, there are concerns that the crimping may cause 
damage to the tissue and possibly affect long-term durability [35, 36]. 
As a less invasive alternative to heart valve replacement surgery, transcatheter valve 
replacement allows patients who pose a high surgical risk to receive valve replacements 
they would otherwise not receive. While promising, studies have shown that some patients 
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undergoing transcatheter valve replacement have died soon after the procedure, and others 
show no improvement in valve functionality or quality of life [37]. Despite advances in the 
transcatheter delivery mechanism, stroke remains the major complication for transcatheter 
valve replacement [28]. While over 50,000 adult patients have received transcatheter valve 
implants since 2002, transcatheter technologies for pediatric patients with congenital heart 
disease are severely lacking [38]. Recently a study for by Driessen-Mol et al. investigated 
the long-term functionality of a tissue engineered transcatheter valve, which could 
overcome the limitations of current transcatheter valves that do not have the capacity to 
self-repair [39]. Although the results from this study demonstrated promising tissue and 
self-repair remodeling, there was evidence of paravalvular leakage and regurgitation which 
would need to be investigated [39]. The minimal invasiveness and fast recovery time of 
transcatheter valve replacement can be advantageous for younger patients, especially since 
valve-in-valve procedures are now an option to replace damaged or degraded valve 
prostheses [28, 40]. 
 
Tissue engineered heart valves (TEHVs) can potentially address the shortcomings of 
current implants by incorporating biomaterials with autologous cells that enable growth 
and biological integration. The ideal heart valve prosthesis is anti-thrombogenic, 
biocompatible, durable, resistant to calcification, and exhibits a physiological 
hemodynamic profile [41]. In addition, the valve’s capability to integrate and grow with 
somatic growth would eliminate the need for multiple surgeries children must undergo. 
The overall TEHV should demonstrate excellent hemodynamics and match patient 
anatomy. At a cellular level, the biomaterials used for the TEHV construct should promote 
cellular integration by enabling cell adhesion, proliferation, ECM production, and 
remodeling. Most importantly, the scaffold must promote physiological cell phenotype and 
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degrade at a rate that matches ECM production. Despite advances, there are no 
commercially available valves that meet all these requirements.  
Biomaterials suitable for TEHVs fall under several classes: decellularized 
extracellular matrix (ECM; xenografts or homografts), natural polymers, and synthetic 
polymers. The different classes of biomaterials are discussed in detail in Section 3.10 and 
3.11. In addition, the fabrication process for each biomaterial type is taken into 
consideration, as it can influence cellular behavior, cell viability, mechanical properties, 
and long-term durability of the scaffold. Thus, when designing a TEHV, there are three 
main design considerations for choosing a biomaterial: 1) cellular interaction and response 
to scaffold; 2) fabrication process and its impact on the microarchitecture of scaffold; 3) 
long-term mechanical properties and function in a physiological setting. These three main 
design criteria will be further discussed in the next section.  
 
There are several design criteria for tissue engineering heart valve scaffolds. A 
TEHV must be non-immunogenic, non-thrombogenic, biodegradable, must promote 
cellular proliferation and viability, and must be functional in physiological conditions. In 
this section, an overview of cells, structure, and function of native valves are discussed. 
Subsequently, a detailed summary of the design considerations for TEHVs and an overview 
of the current state of the field is provided.  
 
Heart valves are populated with cells that maintain the strength and durability 
required for repetitive stress and strain over a lifetime.  This is accomplished by cells that 
actively produce and remodel the extracellular matrix (ECM) of the leaflets to repair 
damages sustained from constant flexion and extension of the leaflets [42-44]. The two 
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major cell types important for tissue homeostasis are valvular interstitial cells (VICs) and 
valvular endothelial cells (VECs) (Table 2). Apart from those two cell types, there is also 
evidence of smooth muscle cells (SMCs) and nerve cells [19, 45]. Thus,  the cell source 
used in TEHVs is an important component for long-term durability, as the lack of cells in 
valve prostheses have been shown to be the main source of failure for mechanical and 
biological implants [10].  
Table 2. Properties of Valvular Interstitial Cells and Valvular Endothelial Cells. 
Reproduced with permission.[44] Copyright 2016, Wiley. 
Characteristic Valvular interstitial cells Ref.  Valvular endothelial cells Ref. 
Cell of origin Blastocytes → embryonic stem 
cells → endocardial epithelial 
cells → mesenchymal cells → 
VICs 
[46] Blastocytes → embryonic stem 
cells → endocardial endothelial 
cells →VECs 
[47]  
Morphology Round, rhomboid, tail and 
spindle-shaped 
[48] Cobblestone, elongated, 
marginal folds and surface 
micro-appendage shape 
[49]  
Metabolic activities Lysyl oxidase and prolyl 4-
hydroxylase production, matrix 
metalloproteinases and tissue 
inhibitors of metalloproteinase 
expression, p38 mitogen-
activated protein kinase synthesis 
[50-52] von Willebrand factor 
production, angiotensin-
converting enzyme activity, 
prostacyclin biosynthesis, 
endothelial nitric oxide synthase 
production 
[49]  
Major phenotypes Fibroblasts (vimentin), smooth 
muscle cells (actin), osteoblasts 
[48]  
[53, 54] 
Smooth muscle cells (actin, 
myosin), fibroblasts (vimentin), 
endothelial cells 
[55]  
Communication Adherens junctions, gap junctions [56] Gap junctions, tight junctions [57]  
Contractility Epinephrine or angiotensin II 
stimulation 
[58] Vasoactive agents [59]  
Immunogenicity Induce donor-specific T cells [60]  Induce CD4+ T cells [61]  







Role in valve 
disease 
Adverse environment causes 
them to remodel the ECM by 
secreting growth factors and 




Adverse environment causes 
ECM deposition, oxidized 
lipoprotein accumulation leading 
to different diseases 
[65]  
Response to disease Both repairing and damaging 
roles related to calcification 
[66]  Expression of calcification-
inhibitory proteins 
(osteoprotegerin), angiogenesis 





Valvular interstitial cells make up a heterogeneous cell population found 
throughout the leaflet. These cells can have a spectrum of sub-phenotypes resembling 
mesenchymal stem cells, fibroblasts, and smooth muscle cells [19]. VICs behave similarly 
to mesenchymal stems cells as they are able to differentiate into osteoblasts, adipocytes, 
and chondrocytes [19, 69, 70]. They also exhibit fibroblast-like properties through their 
ability to synthesize extracellular matrix proteins such as collagen, glycosaminoglycan, and 
elastin; however, VICs are distinct from other fibroblasts such as pericardial or dermal 
fibroblasts [48, 71]. Previous studies have also identified VICs to have positive expression 
of alpha smooth muscle actin (aSMA) and expression of contractile proteins, a 
characteristic of SMCs and "activated" fibroblasts [72].  
Although not fully understood, VICs have dynamic phenotypes which are 
categorized under five sub-phenotypes: embryonic progenitor endothelial/mesenchymal 
cells, quiescent VICs, activated VICs, progenitor VICs, and osteoblast VICs [48]. The cell 
plasticity of VICs is necessary for the development and maturation of valves but can also 
play a role in pathological progression.  In developing valves, VICs are in an activated state 
with expression of aSMA and vimentin [48]. Meanwhile, healthy valve cells only express 
vimentin, suggesting cells are quiescent and fibroblast-like. In the diseased state, VICs are 
contractile due to higher expression of aSMA. They also have higher levels of ECM 
production and secretion of cytokines, proteases, and growth factors [48, 73]. If activation 
persists, VICs can transdifferentiate into osteoblast-like cells, which have been associated 
with calcific nodule formation and heart valve calcification [73]. 
The activation of VICs, production of ECM, and secretion of matrix remodeling 
enzymes can be regulated by the presence of different bioactive molecules as well as 
mechanical stretch [74-77]. VICs have the capacity to respond to local cellular, 
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microstructural, and hemodynamic environments through cell-cell and cell-matrix 
interactions. Cell-cell interaction occurs through cadherins, desmosomes, and gap 
junctions [78]. However, cellular communication can also occur through paracrine 
signaling. For instance, when VICs were co-cultured with valvular endothelial cells 
(VECs) there was a reduction of VIC activation due to VEC nitric oxide production [79]. 
VICs are also responsive to changes in substrate mechanics. When VICs were cultured on 
higher modulus (15 kPa) scaffolds, more activation was observed compared to substrates 
of 3 kPa [80]. Lastly, the hemodynamic environment VICs are exposed to can influence 
their properties. In a study by Merryman et al., VICs isolated from the left side of the heart 
were stiffer due to a difference in cytoskeletal composition and collagen biosynthesis 
compared to cells from the right side of the heart [81]. 
 
Valvular endothelial cells (VECs) form a cell layer that lines the blood-contacting 
surfaces of the valve leaflets. The monolayer of cells is responsible for rendering the leaflet 
non-thrombogenic. Apart from this, VECs also regulate the immune and inflammatory 
responses and play a role in regulating VIC phenotype through paracrine signaling [41]. 
VECs were traditionally assumed to behave similarly to vascular endothelial cells. While 
there are some similarities such as the expression of Von Willebrand factor, release of nitric 
oxide and endothelin-1, and presence of prostacyclin and gap junctions, there are also 
distinct differences between the two cell types [79, 82-85]. The major difference between 
valvular and vascular endothelial cells is that VECs align circumferentially or 
perpendicular to the direction of blood flow, while vascular endothelial cells align parallel 
to the direction of flow [86-88]. VECs have also been shown to have a higher proliferation 
rate compared to vascular endothelial cells [89]. 
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VECs respond to changes in mechanical environment through the activation of 
mechanotransduction pathways, which are detected in the blood flow through 
glycoproteins on the surface of endothelial cells [90]. As a result, flow-mediated 
mechanotransduction can result in the activation of protective or pathological signaling 
pathways [91]. For instance, a study demonstrated that changes in shear stress led to 
morphological changes in VECs, which can result in cell dysfunction and pathogenesis 
[59]. VECs are also important for modulating VIC function through paracrine signaling. 
As mentioned before, NO production of VECs is protective in that it maintains VICs in a 
quiescent phenotype [92]. Meanwhile, when VECs become dysfunctional, VICs have been 
shown to exhibit a more activated phenotype with elevated expression of  aSMA [93]. 
Furthermore, VECs appear to have different phenotypes and genetic profiles depending on 
their location on the aortic valve leaflets. This may be because the aortic side of the leaflets 
experience disturbed flow when the valve closes during diastole, while the ventricular side 
experiences steady pulsatile flow, promoting a more protective phenotype [59]. 
 
The cell source selected for tissue engineering heart valves will greatly impact the 
likelihood of their success. Thus, there are several considerations for selecting a cell source. 
First, the type of cell is important to consider as there are three main options: xenogeneic, 
allogenic, and autologous. While xenogenic sources may be readily available, long-term 
they are not a viable clinical translational option. Allogenic cells are also not ideal as they 
can invoke an immune response and would require long-term immunosuppressive therapy. 
Thus, autologous human cells would be optimal for creating a TEHV.  
The characteristics of the cell source are significant considerations for TEHVs. The 
ideal cell source for seeding TEHVs would be one that can be expanded sufficiently and 
has the potential to be differentiated into the two main cell types found in heart valves, both 
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VECs and VICs. If these cells are to be differentiated, it is important to characterize their 
phenotype and biological function. From our review of VECs and VICs, we understand 
that the phenotype of valve cells is very dynamic and easily impacted by extrinsic factors. 
The reason for these changes in phenotype is not yet fully understood. Thus, there is no 
direct metric to determine if differentiated cells from other sources are “truly” valve cells. 
The only method to characterize these cells is to identify similarity in their function, surface 
markers, and genetic profile. VICs are known to have expression of aSMA during an 
activated state. Another phenotype characteristic is the expression of prolyl 4-hydroxylase, 
which indicates collagen synthesis [72]. 
However, the cellular function may be the most important factor to consider. For 
instance, VECs regulate permeability, both immune and inflammatory responses, and VIC 
phenotype through paracrine signaling [44]. Meanwhile, VICs maintain tissue homeostasis 
by high proliferation activity and ECM repair and remodeling. The activation of VICs 
should be managed, as the persistence of a myofibroblast phenotype can result in 
upregulation of cell proliferation and ECM production, which has been associated with 
VIC transdifferentiation into osteoblast-like cells and ultimately, valve calcification. The 
cell source is an important component of the TEHV, with its success being dependent on 
the effects of the scaffold’s micro- and macro-structure and bioactivity.   
 
A number of cell sources have been applied to tissue engineering heart valves, with 
most of them coming from animal sources such as porcine, bovine and ovine. (Table 3) 
[44]. These cell types are frequently used because they are easily accessible and 
economical. Previous studies have used mesenchymal stem cells (MSCs), VICs, VECs, 
endothelial progenitor cells, bone marrow progenitor cells, autologous amniotic fluid cells, 
myofibroblasts, and smooth muscle cells [44]. Similar cell types were also investigated 
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using human cell sources. The important take away from past studies is that each cell type 
has advantages and disadvantages. For instance, MSCs collected from bone marrow 
resembled fibroblasts and had multi-lineage differentiation potential. When MSCs were 
cultured on different scaffolds such as polyglycolic acid (PGA) with poly-l-lactic acid 
(PLLA), cells under mechanical stimulation demonstrated collagen deposition similar to 
VICs [94]. In another case, autologous amniotic fluid cells were used to seed a trileaflet 
valve composed of polyglycolic acid and poly-4-hydroxybutyrate (PGA-P4HB). After 1 
week of implantation in utero, scaffolds demonstrated cellular integration characterized by 
increased cellularity and GAG content [95]. Furthermore, human fibroblasts and 
endothelial cells isolated from saphenous veins were used to seed a polyurethane 
nanofibrous scaffold [96]. The fibroblasts were able to spread on the fibrous scaffold, while 
the endothelial cells formed a monolayer over the fibroblasts. The cells responded better 
to a dynamic culture setting, showing more proliferation and ECM production [96]. 
Although these studies are promising, the direct application of primary cells for TEHVs 
may not be suitable for clinical translation, as allogenic cells can induce an immune 
response in the recipient of the TEHV [44]. Also, primary cells have limited proliferation 
capabilities, while stem cells can result in uncontrollable proliferation [44]. These are some 
limitations that need to be considered when selecting a cell source for TEHVs. While we 
do not report extensively on cell types for TEHVs, more information can be obtained by 






Table 3. Cell types used for tissue engineering heart valves. 
 
In the heart, there are four valves: the tricuspid and mitral valves control blood 
flowing from the atrium to the ventricles, while the pulmonary and aortic valves regulate 
blood from the ventricles to the pulmonary artery and the aorta, respectively. The tricuspid, 
pulmonary, and aortic valves are composed of three leaflets. Meanwhile, the mitral valve 
has two cusps that have chordae tendineae attached to the posterior surface of the valve to 
prevent the cusps from prolapsing.   
Reproduced with permission.[44] Copyright 2016, Wiley. 
Cell type Organ source (tissue/animal) Ref. 
Animal sources     
Mesenchymal stem cell Bone marrow/ovine [97]  
Valvular interstitial cell Aortic valve/porcine [98, 99]  
Valvular endothelial cell Aortic valve/bovine [100, 101]  
Endothelial progenitor cell Peripheral blood/sheep [102]  
Endothelial cell Carotid artery/lamb [103]  
Bone marrow progenitor cell Bone marrow/lamb [104]  
Autologous amniotic fluid cell Amniotic fluid/sheep [95]  
Smooth muscle cell Aortic root sinus/porcine [105, 106]  
Myofibroblast Aortic wall/porcine [107]  
Human sources 
Mesenchymal stem cell Bone marrow [108, 109]  
Adipose tissue [110, 111]  
Umbilical cord matrix [112]  
Umbilical cord blood [113]  
Amniotic fluid [114]  
Chorionic villi [115]  
Endothelial progenitor cell Amniotic fluid [116]  
Peripheral blood [117]  
Umbilical cord blood [112]  
Valvular interstitial cell Aortic valve [118]  
Induced pluripotent stem cell Skin (fibroblasts) [119]  
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The mechanical strength of valves is attributed to the structure of the layers in the 
leaflet, and more specifically, the arrangement and orientation of the ECM. The thickness 
of valve leaflet ranges between 300 to 700 µm and is composed of collagen type I/III, 
proteoglycans, glycosaminoglycans (GAGs), and elastin [72]. The leaflet is comprised of 
three layers known as the fibrosa, spongiosa, and ventricularis (Figure 2) [10, 41, 120]. An 
important feature of the valve leaflets is the microstructure in each of the three layers of 
the leaflet. The fibrosa layer makes up almost half of the leaflet thickness, where dense 
collagen type-I fibers are aligned in a circumferential direction [19, 121].  The highly 
organized structure of the collagen fibers enables the fibrosa to be the load-bearing layer 
during diastole [85, 122]. The spongiosa is the middle layer rich in glycosaminoglycans, 
Figure 2. Anatomical structure of aortic valve and a cross‐sectional view of the three layers 
of the valve leaflet.   A) There are three leaflets in the aortic valve, which open and close 
to allow for unidirectional blood flow. Each leaflet is composed of three layers known as 
the fibrosa, spongiosa, and ventricularis. The fibrosa layer has collagen fibers aligned in 
the circumferential direction, while the ventricularis is composed of elastin fibers aligned 
in the radial direction. Valvular endothelial cells line the outer layers of the fibrosa and the 
ventricularis, and within the valve leaflet, there are valvular interstitial cells. 
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known to act as a lubricant between the two leaflet layers [123]. Furthermore, the 
ventricularis layer has elastin fibers radially aligned, providing the leaflets with elastic 
properties [85, 121]. 
 In a study to characterize the mechanical properties of the valve leaflets using 
uniaxial tensile testing, it was observed that the leaflets experience about 1-2 MPa in the 
radial direction and 8-12 MPa during the nonlinear transition [85, 123, 124]. However, at 
physiological stress and strain, the leaflets can experience about 200 - 400kPa in stress, 
and about 0.1 and 0.4 in strain in the circumferential and radial directions, respectively 
[85]. At a cellular level, one study showed that the modulus of each individual layer of the 
leaflet varied. For instance, in porcine valves, the ventricularis ranged between 8 to 17 kPa, 
the spongiosa ranged between 5 to 7 kPa, and fibrosa ranged between 8 to 19 kPa [125]. 
The stiffness of each layer of the leaflet was determined via atomic force microscopy 
(AFM), which has inherent limitations. These ranges should be used as a guide as there is 
evidence from finite element (FE) analysis that despite each layer having unique features 
they function as a homogenous structure during deformation rather than a heterogenous 
structure [126]. The properties of the ECM should be carefully designed to mimic the 
macro function of the leaflets.  
 
Despite efforts in the field of TEHVs, the ability to successfully replicate the 
trilayer leaflet structure remains a challenge. The structure of the valve leaflets significantly 
impacts its ability to mechanically function in physiological conditions. The most 
important design criterion for developing functional leaflets is the anisotropic properties 
observed in native valves. Anisotropy is achieved by the different orientations of collagen 
and elastin fibers. To replicate this property, a fabrication process that can reproduce these 
unique orientations will need to be identified and implemented. Furthermore, the overall 
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mechanical properties need to be within the 200 - 400 kPa range for proper function in 
physiological conditions, as stated previously [85]. At a cellular level, cells experience a 
modulus that is magnitudes lower. This is an important consideration as previous studies 
have demonstrated that VICs transition to a myofibroblast phenotype when cultured on 
stiffer surfaces [127, 128]. In summary, the anisotropic properties, overall modulus of 200-
400 kPa, and ability to sustain a healthy cell phenotype are all properties that should be 
considered in the design of TEHVs. 
 
In an attempt to recapitulate the anisotropic properties and microstructure of the 
valve leaflet, several studies have investigated methods of introducing multiple layers to 
the valve leaflet design. In the past, studies focused on first developing single-layer 
designs, as fabrication processes were limited. With the advancement of fabrication 
techniques and materials science, there have been several groups that developed and tested 
multilayered scaffolds for TEHVs. For instance, the electrospinning technique using 
materials such as poly-ε-caprolactone (PCL) enables the formation of aligned nanofibers 
[129]. These aligned scaffolds introduce anisotropic properties similar to native valve 
leaflets. Modification to electrospun scaffolds and addition of other materials have since 
been introduced to generate more complex structures that resemble the three layers of the 
leaflet [118, 130]. An example of this is a trilayer elastomeric scaffold created by Masoumi 
et al., where poly (glycerol sebacate) (PGS) was molded into a diamond-like shape using 
microfabrication processes. This scaffold was then assembled to generate a PGS scaffold 
with electrospun PGS/PCL sandwiched in between. This generated a tunable, elastic, 
anisotropic scaffold that supported cellular function and activity. The scaffold was tested 
functionally in an ex vivo model, where the trilayer leaflet outperformed the single layer 
PCL-only scaffold [118]. 
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When generating complex structures composed of different materials, the 
interaction between layers is another important consideration. One study demonstrated that 
a trilayer hydrogel quasilaminate can be generated using poly (ethylene glycol) diacrylate 
(PEGDA) and a sandwich fabrication method [131]. The scaffold was composed of two 
stiff hydrogel outer layers and one soft hydrogel component to represent the spongiosa 
layer. The quasilaminate scaffold did not experience any issues between the interface of 
the layers and did not vary in bending moduli compared to its single layer counterpart. 
However, a main takeaway from this study is that when cells were introduced to the trilayer 
scaffold, the modulus decreased [131]. Another fabrication process that enables structure 
and anisotropic properties to be introduced is the application of 3D printing. Additive 3D 
printing can enable scaffolds of intricate designs to be fabricated, where the microstructure 
and alignment of fibers can be printed with spatial placement of specific cell types [132]. 
While 3D printing enables significant complexity to be introduced to the scaffold, this 
process is still in the development phase. The biomaterials needed to create these scaffolds 
must first be optimized for the 3D printing process.  
There are several different fabrication processes used to generate biomimetic 
scaffolds resembling the three layers of the valve leaflet. While some techniques, such as 
electrospinning, introduce the anisotropic properties, the fabrication process may not 
suitable for generating a scaffold with cells encapsulated within it. Therefore, when 
designing the structure of the TEHV, the method in which scaffolds will be fabricated have 
to be carefully considered, as it can affect overall mechanical properties, anatomical 
structure of the scaffold, and cellular activity.  
 
Healthy heart valves are essential for proper heart function. In an average lifetime, a 
person’s heart valves will open and close nearly 3 billion times, allowing 3-5 L of blood to 
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circulate through the body [85, 133]. Valves rely on the inertial forces from blood flow to 
open and close, passively ensuring unidirectionality during the cardiac cycle. The 
semilunar valves (pulmonary and aortic) prevent blood from flowing back into the 
ventricles, while the atrioventricular valves (tricuspid and mitral) prevent blood from 
flowing back into the atria from the ventricles. To sustain such an important function in the 
cardiac cycle, heart valves must be able to withstand many forces of the hemodynamic 
environment within the heart, a feat made possible as a result of its structure.  
 
In the aortic valve, the leaflets of the valve are closed during diastole, slightly 
overlapping in a region called the lunula to allow the filling of the left ventricle. The valve 
annulus then expands in radius until a small orifice is present, and blood begins to flow 
through the orifice as the ventricle contracts during systole [85]. During this contraction, 
the aortic valve opens, and blood flows through the valve, traveling up to 1.35 ± 0.35 m/s 
[134]. At the end of systole, the deceleration of blood flow allows for the coaptation of the 
valve cusps. The aortic sinuses are particularly important in this function. Pressure 
differences cause blood along the aortic wall to reverse direction, creating vortices on the 
leaflets facing the aorta, leading to the closure of the valve leaflets. In addition, vortices 
create a small pressure gradient across the leaflets and push them into their closed position 
[85, 133]. 
 
During the cardiac cycle, valves experience stresses and strains as a result of blood 
flow and pressure gradients between the chambers of the heart. Arjunon et al. described 
three mechanical stimuli experienced by heart valves: shear stress, pressure, and leaflet 




Shear stress in valves is defined as the frictional stresses that the leaflets experience 
due to blood flow during the cardiac cycle. While shear stresses on the walls of the aorta, 
proximal to the leaflets, are well described, only a few attempts to measure shear stresses 
on aortic valve leaflets have been reported. One group conducted studies on the shear 
stresses experienced by the different surfaces on aortic valve leaflets. They reported that 
shear stresses experienced by the ventricularis were unidirectional, whereas those 
experienced by the fibrosa were oscillatory and dependent on hemodynamics [135, 136]. 
In these studies, they reported that the highest shear stresses experienced by the 
ventricularis were 80 dynes/cm2 during systole, and during diastole, the fibrosa 
experienced shear stresses of about 23 dynes/cm2 [135, 136]. In a diseased or defective 
state, leaflets may experience higher levels of shear stress due to altered hemodynamics 
Figure 3. Shear stresses and strains experienced by aortic valve leaflets.  
Stress and strain during a) systole, b) diastole, and c) diastole, from a top view. Adapted 
under the terms of the Creative Commons Attribution License [1]. Copyright 2013, Back 
et al. 
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[42]. It is also suggested that reduced shear stresses can lead to calcification of the leaflet 
[137]. 
During diastole, heart valves experience transvalvular pressure gradients ranging 
from 10 mmHg to 120 mmHg [133]. The aortic valve, in particular, experiences a 
transvalvular diastolic pressure gradient of 80 mmHg [42]. The ability to sustain this 
pressure is due to circumferentially aligned collagen fibers in the fibrosa layer of the 
leaflets [138]. In the case of varying degrees of aortic stenosis or hypertension, 
transvalvular pressure gradients can increase depending on the severity of the disease [42]. 
Strain, a measure of deformation, in aortic valve leaflets is largely determined by 
tissue structure. In the circumferential direction, collagen fibers provide tensile strength. 
Alternatively, elastin fibers mainly oriented in the radial direction lead to greater strain 
experienced in this direction. Strain in the circumferential and radial directions were 
reported to be 10% and 40%, respectively [139-141]. 
 
TEHVs must be designed to offer a significant increase in function compared to the 
diseased valve while simultaneously integrating with the patient’s body, a task not yet 
accomplished by mechanical or biological valve implants. Above all, TEHVs must ensure 
the functionality of the valve by passively maintaining unidirectional blood flow. In order 
to achieve this functionality, TEHVs must be designed with several considerations in mind. 
First and foremost, TEHVs must be able to withstand the inertial forces of blood flow in 
the hemodynamic environment of the heart, using them to open and close passively. Blood 
flow out of the left ventricle during systole should passively open the TEHV. By mimicking 
the general anatomy of the valve leaflets and sinuses, vortices due to back flow of blood at 
the end of systole, in addition to those as a result of pressure gradients between heart 
chambers, should cause the TEHV to close fully.  
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In the closed state during diastole, TEHVs must be able to withstand a transvalvular 
pressure gradient of 80 mmHg. Upon opening, TEHV leaflets will experience 
unidirectional shear stress on the ventricularis surface and oscillatory shear stress on the 
fibrosa surface, and such shear should not cause damage to the leaflets, nor should it 
stimulate the progression of disease, such as calcification. Lastly, leaflets should display 
anisotropic properties, particularly regarding strain in the circumferential and radial 
directions, as these properties are important in ensuring valve functionality and preventing 
pathological conditions from developing on the cellular level [42]. 
 
Because healthy human heart valves are difficult to obtain, the mechanical 
properties of valve leaflets and the mechanical stimuli they experience have yet to be fully 
investigated. In comparison, studies in the functionality of TEHVs are even more lacking, 
as complete, functional valve structures have yet to be fabricated. Some groups that have 
investigated the functionality of their tissue engineered scaffolds include Engelmayr et al. 
[142], Driessen et al. [143], and Alavi et al. [144]. A few studies of TEHV implantation 
into animal models have been conducted by Sodian et al. [145]. Hoerstrup et al. [146], and 
Kluin et al. [147]. 
Engelmayr et al. created a bioreactor to simulate cyclic flexure to test heart valve 
scaffolds made of PGA fibers and a 50:50 blend of PGA and PLLA fibers, coated in P4HB 
to allow molding into different shapes. From this study, they determined that dynamic 
flexure significantly decreases the stiffness of their scaffolds after 1 week compared to 
those in static conditions, due to fiber fragmentation observed in SEM images of the 
scaffolds [142]. This suggests that dynamic testing is necessary to evaluate the 
functionality of TEHVs in a physiological setting, as TEHV behavior may not be truly 
represented in static testing conditions. Driessen et al. aimed to model the mechanics 
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TEHV leaflets and created scaffolds PGA coated in P4HB seeded with human cells and 
conditioned in a diastolic pulse duplicator. Over 4 weeks, the conditioned leaflets became 
thinner. Uniaxial tensile tests were performed on the conditioned leaflets, and the results 
were used to develop a model to analyze TEHV mechanics. In addition to less coaptation 
of the engineered scaffolds, these results indicated that the tissue engineered leaflets were 
stiffer and less anisotropic compared to native porcine valve leaflets [143]. Alavi et al. 
designed many different nitinol mesh leaflets, conditioned in a pulse duplicator to 
determine which leaflets functioned most similarly to the native valve. Accelerated wear 
tests were then conducted on the best scaffolds to determine their durability, and computer 
simulations revealed that scaffold design may result in abnormal valve function [144]. 
These studies demonstrate the importance of testing the functionality of TEHVs in dynamic 
conditions and indicate a need for more appropriate scaffold designs to replicate the 
functionality of native valves. 
Only a few studies involving TEHV implantation into animal models have been 
conducted to date. Sodian et al. created polyhydroxyoctanoate (PHO) scaffolds with ovine 
carotid arterial cells and implanted the scaffolds into 6 sheep. These valve scaffolds 
resulted in no stenosis or thrombosis for 20 weeks, but they degraded slowly, resulting in 
prolonged bioabsorption of PHO [145]. Hoerstrup et al. created a PGA mesh coated with 
P4HB, which resulted in faster degradation of the scaffold that was higher in strength and 
flexibility. These valve scaffolds resembled native heart valves in structure, mechanics, 
and composition, and they remained functional in sheep for 5 months [146]. More recently, 
Kluin et al. implanted an electrospun polycarbonate bis-urea (PC-BU) valve into the 
pulmonary position of sheep for up to 12 months. During this time, the subjects did not 
show signs of valve failure, and the implanted scaffolds had cell infiltration into the porous 
microstructure. The evidence of collagen, GAGs, and elastin deposition similar to native 
valves was thought to contribute to the successful functionality of these valves [147]. 
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While the field of TEHVs is rapidly advancing, many TEHVs have yet to be studied 
for functionality. As more groups are successful in designing functional TEHV scaffolds, 
studies regarding the mechanical properties and the effect of hemodynamics on these 
scaffolds must be conducted to determine their suitability for implantation in humans.  
 
 
To create functional TEHVs, it is important that TEHV scaffolds experience 
physiological hemodynamic conditions, as the stresses and strains on valves during the 
cardiac cycle is essential to inducing proper cellular behavior. Dynamic bioreactors serve 
an important role in this process. In addition to making it possible to observe initial leaflet 
functionality, they can also condition scaffolds over time, allowing cells to produce ECM 
that may enhance mechanical properties prior to implantation. Because hemodynamic 
behavior around valves is quite complex, many different bioreactors have been created to 
mimic the conditions that native valves experience, including cyclic stretch and flexure, 
oscillatory shear stress, and pressure, and more are in development. 
In 2000, Hoerstrup et al. developed a pulsatile flow bioreactor in order to stimulate 
TEHV scaffolds to increase in mechanical strength through ECM production, while 
enabling a more complete degradation of the polymeric scaffold. This bioreactor consisted 
of an air chamber and a fluid chamber separated by a silicone rubber diaphragm, which 
caused pulsatile flow when displaced periodically [148]. For less mechanically robust 
TEHVs made of materials such as hydrogels, Jockenhoevel et al. created a bioreactor 
consisting of a laminar flow chamber to introduce shear stress to fragile scaffolds [149]. 
Soon following, Engelmayr et al. reported a bioreactor design to provide cycle flexural 
stimulation to TEHV scaffolds in order to observe changes in effective stiffness of the 
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scaffold due to unidirectional cyclic flexure [142]. To study the effects of conditioning 
scaffolds with only some of the mechanical cues present during the cardiac cycle, Mol et 
al. designed a diastolic pulse duplicator, a bioreactor that only mimics the diastolic phase 
of the cycle and conditions scaffolds using a strain-based approach [150]. Alternatively, 
Engelmayr et al. designed the Flex-Stretch-Flow (FSF) Bioreactor in order to study the 
coupled effects of cyclic flexure, stretch, and flow on TEHVs [151]. In addition, Syedain 
et al. created a cyclic stretch bioreactor consisting of the TEHV mounted in a latex tube 
that is cyclically pressurized by culture media, stretching the valve root and leaflets with 
the latex. 
More recently, Ramaswamy et al. designed a more physiologically relevant 
bioreactor that would allow for higher fluid velocities and subject scaffolds to higher shear 
stress while maintaining laminar flow [152]. Converse et al. identified a problem with 
bioreactors in that most of the ones that have been developed are complex and suited for 
Figure 4. Disposable bioreactor designed by Converse et al. This bioreactor design consists 
of (a) the seeding chamber, (b), the pulsatile chamber, and (c) the cap. TEHV conditioning 
in the disposable bioreactor is shown on the right. Reproduced with permission [2]. 
Copyright 2015, Wiley. 
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bench research, rather than clinical application. Current bioreactors utilize flow-loops to 
mimic circulation, which increases system complexity, and they are designed to be re-
sterilized and re-used. From a regulation standpoint, this is undesirable because re-
sterilization and re-use increases the risks of disease transmission in between scaffolds 
during seeding and conditioning. This serves as a hindrance for the clinical development 
of patient-specific TEHVs, so alternative designs must be pursued to make this process 
clinically translatable. To address this issue, Converse et al. developed a disposable 
bioreactor system consisting of three parts: a seeding chamber where cells can attach to the 
scaffold, a pulsatile chamber for mechanical condition, and a cap where the scaffold 
attaches to allow movement between chambers. A screw driven actuator compresses and 
expands a bellows to generate pulsatile flow of culture medium (Figure 4) [153]. Alongside 
the rapid development of TEHVs, bioreactors have also been improved to better mimic 
physiological hemodynamics and to be more applicable outside of bench research, as 
TEHVs come closer to reaching the clinic. 
 
Prior to implantation in humans, TEHVs must be evaluated in animal models to 
ensure that they can function long-term with matrix remodeling and tissue growth without 
entering a diseased state. Ideally, primates would serve as the best models to observe 
TEHVs in vivo long-term because they closely resemble humans anatomically and 
physiologically, but they are expensive to purchase and maintain, and their use is heavily 
restricted by ethics [154]. For this reason, smaller mammals are used, such as pigs, calves, 
and sheep. The most commonly used animal model for studying TEHVs is the adult sheep. 
Sheep have been widely used because they have high calcium metabolism, making them 
valuable for observing TEHVs for durability and sustained performance under “worst case” 
conditions [155]. However, this characteristic of ovine models may lead to increased 
fibrosis of the valve, and therefore, sheep are not a proper representation of valve tissue 
32 
remodeling and regeneration in humans [156]. In addition, sheep have reduced platelet 
activity  compared to humans, which may result in the failure to reveal the thrombogenic 
potential of TEHVs scaffolds [157]. In vivo studies of TEHVs are limited, but the majority 
of them have been conducted in ovine models [39, 117, 147, 158]. 
More recently, Gallo et al. reported on the potential use of the Vietnamese pig to 
evaluate TEHVs because they possess anatomic features that are very similar to those of 
humans. Compared to common farm pigs, Vietnamese pigs are smaller and do not grow as 
rapidly; they reach about 70 kg during adulthood. Vietnamese pigs are also suitable 
because their cardiac output, stroke volume, mean arterial pressure, heart rate, and 
myocardial blood flow are all comparable to humans, as well as their immune response and 
mechanism of blood coagulation. However, these pigs were reported to be more susceptible 
to endocarditis [159]. While Vietnamese pigs show promise, for now, there is not a 
standard animal model for the evaluation of TEHVs in vivo.  
 
Before highlighting different biomaterials used for TEHVs, there are three main 
techniques for fabricating natural or synthetic scaffolds that will be covered throughout 
this section: molding, fiber spinning, and bioprinting (Figure 5). Scaffolds can be fabricated 
through molding, which is a process where precursor solution is dissolved, poured into a 
mold, and then gelled. This technique is often utilized to generate tubular or planar 
scaffolds [160]. Another mechanism utilized for generating fibrillar scaffolds is 
electrospinning. This fabrication process involves subjecting a polymer solution to an 
electric field. A charged polymer solution is generated when the electrostatic repulsion 
overcomes the surface tension between the polymer and syringe. Once this occurs, jets of 
polymer travel towards a surface, during which the solvent evaporates to generate 
continuous filaments of natural or synthetic material [161]. Bioprinting is a more recent 
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approach used to generate scaffolds for heart valve tissue engineering. 3D bioprinting is an 
additive manufacturing technique that enables complex 3D structures to be generated 
through layer-by-layer deposition of biomaterials, cells, and growth factors [162, 163]. The 
most common types of 3D bioprinting are inkjet, extrusion-based, and laser-assisted 
printing [162]. 
 
Figure 5. Fabrication methods for TEHVs.  A) Molding can be used to generate heart valve 
conduits. A multi-step injection molding technique was utilized to generate a fibrin valve with 
leaflets and aortic root. Color was added for visualization of leaflets. Bottom images 
demonstrate the ability to create two-layered leaflets. Reproduced under the terms of the 
Creative Common Attribution Noncommerical License [99]. Copyright 2015, M. Weber et al. 
B) Copper valve mold was used as the collector for electrospinning PEGdma-PLA to create 
valve conduit. Reproduced with permission [71]. Copyright 2014, Elsevier. C) Top image 
shows a 3D model of a reconstructed aortic valve. The color difference is to distinguish 
different cell sources used for 3D printing scaffold: green represents SMCs and red is for 




The application of natural biomaterials has been used in a variety of tissue 
engineering applications such as wound healing, sutures, bone regeneration, drug delivery, 
and medical devices [164]. Natural materials can be in the form of polysaccharides, 
proteins, and polyesters and are derived from a number of animal sources, plants, algae, 
and fermentation of microorganisms [165-167]. The advantage of natural biomaterials over 
other materials is that they have similar biological macromolecules that are important for 
guiding cells in tissue homeostasis and repair. In addition, the material properties can 
minimize chronic inflammation and immunological reactions. In this section, ECM-
derived natural biomaterials and their applications in heart valve tissue engineering are 
discussed. GelMA will be further discussed in reference to its application to this thesis 
project.  
 
Collagen is the most abundant protein in the body, with more than 28 genetic 
variants [168]. The most common type of collagen is collagen type I, which has been 
extensively studied in tissue engineering applications [169]. The other types of collagen 
are II, III, and V, and they make up components of skin, muscle, bone cartilage, and 
tendons. All variants of collagen are characterized by a triple-helix structure, where each 
single polypeptide chain is composed of a repeating sequence, Gly-Xaa-Yaa. Glycine is 
the smallest amino acid that is found in every third amino acid of the peptide sequence, and 
any amino acid can be found in the Xaa or Yaa positions. More frequently, proline occupies 
the Yaa position, and it is often found as hydroxyproline due to post-translational 
modification. Aside from the frequency of proline and hydroxyproline, there are hydrogen 
bonds that stabilize the triple-helix structure, thus enabling the structure to remain stable at 
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body temperature [170]. When synthesized in vivo, collagen self-assembles into fibrillar 
structures to form collagen fibers that make up the matrix surrounding the cells.  
With collagen being one of the most abundant proteins found in the body, there 
have been many applications in the cosmetic, medical, pharmaceutical, and food industry 
[171]. Collagen can be fabricated into several different forms such as collagen sheets, 
sponges, hydrogels, pellets, or nanospheres. In the case for heart valve tissue engineering, 
collagen is of high interest mainly because the leaflets of the valve are primarily composed 
of collagen type I. Collagen can be extracted and purified from different tissue sources 
[160]. It is also possible to obtain human recombinant collagen; however, the mechanism 
for doing so is expensive and not yet scalable for clinical translation [172]. 
Collagen hydrogels are fabricated by using collagen type I monomers that self-
assemble into fibrillar structures to form a viscoelastic hydrogel. The mechanical properties 
of collagen hydrogels can be tuned through the concentration of monomer, temperature, 
pH, and ionic strength [160, 173]. These conditions can influence the diameter of collagen 
fibers and the overall mechanical properties of the hydrogel [174]. Although the 
mechanical properties are tunable, the elastic moduli of collagen hydrogels are limited to 
10-30 kPa and have an ultimate tensile strength of 5-10 kPa [175]. These properties of 
collagen hydrogels are not representative of natural ECM because lower protein 
concentrations must be used to ensure proper diffusion of nutrients to the surrounding cells 
[85, 176]. 
In heart valve tissue engineering, collagen scaffolds were molded in 2D or 3D 
hydrogels to better understand heart valve biology and the progression of valve disease 
[177, 178]. To develop a scaffold with physiological properties, the temperature, pH, and 
crosslinker concentration has been utilized to modulate the scaffold properties [179-181]. 
In several studies, collagen gels were used to examine cellular behavior and changes that 
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mimic physiological conditions. In one study, collagen gels were used to understand the 
metabolic activity of VICs and VECs co-cultured in the presence of chondroitin sulfate 
[182]. The results of this study demonstrated that collagen constructs were capable of 
contracting similar to mitral valve tissue and were ideal for understanding valve biology. 
In a different study, 3D collagen gels were generated to determine the effects of anisotropic 
strain on VIC phenotype and fibroblastic behavior [183]. This study led to a better 
understanding of how VICs respond to strains, where the phenotype of VICs was 
modulated by anisotropic biaxial strain [183]. 
While electrospinning has been widely applied to tissue engineering, collagen 
electrospinning alone has yet to be applied to heart valve tissue engineering [161, 184].  
However, collagen in combination with synthetic polymers have been used to generate 
nanofibers scaffolds for tissue engineering [185-187]. Meanwhile, extrusion-based 3D 
bioprinting has been used to create collagen scaffolds for tissue engineering applications 
but these scaffolds are less common than scaffolds of other biomaterials such as alginate, 
methacrylated polymers, and synthetic hydrogels [14, 188]. 3D bioprinting is possible with 
collagen only if the pH or temperature are properly controlled [160]. With ideal conditions, 
collagen can take up to half an hour for complete gelation [189]. The most common 
application of collagen for 3D bioprinting is for cartilage or skin tissue engineering and not 
as often for heart valve tissue engineering [190, 191]. Collagen is rarely bioprinted by itself 
but rather with a combination of other materials such as Pluronic, which is used to improve 
the viscosity needed for extrusion [189, 192, 193]. While collagen was not used directly in 
3D bioprinting a heart valve, Duan et al. 3D bioprinted a heterogeneous heart valve using 
gelatin and alginate hydrogels [106]. Gelatin is a denatured form of collagen and has 
similar properties to native collagen. 
There are many advantages and disadvantages to using collagen as a biomaterial 
for tissue engineering heart valves. One advantage of collagen is that it is a native 
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biomaterial in which cells can recognize and interact with. For instance, collagen has a 
peptide sequence Arg-Gly-Asp (RGD) that cells can recognize through integrin-binding. 
This interaction can result in activation of several signaling pathways that can promote 
proliferation, migration, and prevent apoptosis [194, 195]. In addition, VICs are known to 
secrete matrix metalloproteinases (MMPs) that can control collagen scaffold degradation 
[196, 197]. Collagen, a native material found in heart valve leaflets, would be the ideal 
scaffold for tissue engineering heart valves. Although there are several advantages to using 
a natural biomaterial, collagen has major setbacks that limit its capabilities to be used as a 
biomaterial for clinically translatable valves.  
One of the major disadvantages of collagen is the lot-to-lot variation from different 
animal sources and from different tissue samples [171]. Another concern is that collagen 
from other species or even other humans can elicit an immunogenic reaction if there are 
antigens present [160]. Collagen, when exposed to blood, can activate blood coagulation 
pathway through platelet adhesion and aggregation [198]. There are surface treatments to 
make the collagen less thrombogenic or methods to recruit endothelial cells that can 
prevent thrombogenesis [199]. However, a major limitation is the mechanical properties of 
collagen scaffolds. It does not meet the design criteria for heart valve tissue engineering by 
itself and thus modifications or combination with other materials are required to utilize 
collagen as a material for heart valve tissue engineering. 
 
Gelatin is partially hydrolyzed collagen that was originally investigated for its 
application as a cell culture platform. Soluble gelatin retains many of the bioactive features 
of collagen; however, to form hydrogels, the gelatin solution must be cooled to 
temperatures below physiological conditions. As a result, this prompted chemical 
modifications to gelatin to generate a robust tunable hydrogel. The most common 
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modification to gelatin is methacrylation, where methacrylic anhydride is mixed with 
gelatin solution to generate gelatin methacrylate (GelMA) [200]. The ability to tune the 
mechanical properties of gelatin using photopolymerization has led to its application in 
bone, cartilage, tissue culture platforms, and tissue engineering [201-203]. Gelatin 
scaffolds have been designed to be either porous or fibrous, depending on application.  
As for TEHV, GelMA has been incorporated into polymer blends to improve the 
viscosity for 3D extrusion-based printing and to introduce biological active sites for 
enhanced cell viability [106]. Another application of GelMA is to study VIC behavior and 
the effects of different biomolecules.  For example, different fibrotic growth factors were 
incorporated into the 3D hydrogel [204]. VICs were able to exhibit a fibroblast-like 
phenotype within two weeks of cell culture. When TGF-B1 was incorporated into the 
GelMA, VICs differentiated into a myofibroblast phenotype with upregulation of α-SMA, 
MMPs, and migration [204]. These two applications of GelMA demonstrate that gelatin 
can be modified and tuned for in vitro studies and possibly for the development of a 3D 
valve conduit. The advantage of using gelatin is similar to collagen in that it contains 
bioactive molecules that promotes cell adhesion, proliferation, and migration. However, 
gelatin is mechanically weak and requires chemical modification or addition of other 
materials for it to form a hydrogel. Thus, the best application of gelatin is to introduce 
biological activity to a scaffold or to be used as an additive for modifying physical 
properties of a polymer blend for 3D bioprinting.  
 
Due to the inadequate mechanical properties, lack of tunability, and batch-to-batch 
variation of natural biomaterials, synthetic biomaterials have been pursued for TEHV 
fabrication. Two main categories of synthetic polymers have been used extensively for this 
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purpose, those that can be crosslinked into hydrogel scaffolds, and those that can be made 
into mechanically stiffer scaffolds that degrade by hydrolysis. 
 
Hydrogels are studied extensively in the field of tissue engineering due to their 
elasticity, high water content, and biocompatibility. As opposed to hydrogels made of 
natural materials, synthetic hydrogels have been pursued in tissue engineering endeavors 
for their tunable mechanical properties. Two types of synthetic hydrogels have been used 
widely to fabricate heart valves: poly(ethylene glycol) (PEG) and poly(vinyl alcohol) 
(PVA). In particular, PEGDA will be further discussed in reference to its application to 
this thesis project.  
 
 
Figure 6. The chemical structure of linear and branched PEG with functional groups, 
represented by R and R’.  Reproduced with permission [225]. Copyright 2010, Elsevier. 
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Poly(ethylene glycol) (PEG), also known as poly(ethylene oxide) (PEO), is the 
most commonly studied synthetic hydrogel for TEHVs. PEG is formed by the 
polymerization of ethylene oxide, and in its most basic form, contains hydroxyl groups on 
each end. It is hydrophilic and can be linear or branched. In place of the hydroxyl groups, 
PEG polymers can be functionalized with different groups such as methoxy, carboxyl, 
amine, thiol, azide, vinyl sulfone, acetylene, and acrylate (Figure 6) [205]. PEG-diacrylate 
(PEGDA) is particularly useful, as PEGDA can be photocrosslinked, and it is formed by 
the reaction of PEG with acryloyl chloride. For TEHV applications, PEG hydrogels are 
commonly fabricated by crosslinking PEGDA with exposure to UV or white light in the 
presence of their respective photoinitiators: 2-hydroxy-4′-(2-hydroxyethoxy)-2-
methylpropiophenone (Irgacure 2925) for UV light, and triethanolamine, Eosin Y, and N-
vinyl pyrrolidone for white light [206]. PEGDA undergoes a rapid and random free radical 
propagation and termination, known as chain-growth polymerization [205, 207]. This 
polymerization method results in a heterogeneous polymer network. Photo-crosslinked 
PEG hydrogels are not readily degradable in their most basic form, but PEG-based block 
polymers with terminating acrylate groups can be both crosslinked and degradable, 
depending on the composition of the block copolymers [208]. 
PEG hydrogels are popular for various tissue engineering purposes because they 
are biocompatible, non-immunogenic, and FDA approved for internal use. They are also 
very versatile as their mechanical, structural, and degradation properties can be tuned using 
a variety of methods [206]. However, PEG hydrogels are bioinert due to their 
hydrophilicity, meaning cells will not readily attach to the surface. Therefore, tissue 
engineering using PEG hydrogels requires the addition of bioactive molecules to the 
hydrogel, such as RGD, a peptide found on fibronectin that promotes cell adhesion and 
migration [205]. 
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In recent years, many studies have been conducted on the ability of PEG hydrogels 
to maintain the phenotype of native cells in heart valves, as well as promote the production 
of ECM. Wang et al. demonstrated that VICs from porcine aortic valves maintain their 
quiescent fibroblast phenotype much better when cultured on PEG hydrogels as opposed 
to stiff plastics and suggest that the fibroblasts sense the elasticity of the surfaces by the 
PI3K/AKT pathway [209]. This is an important observation, because the maintenance of 
quiescent VICs is essential to normal valve function; VIC differentiation into 
myofibroblasts can lead to valvular fibrosis [209]. In a similar study, VIC differentiation 
was moderated by VECs cultured on PEG hydrogels of different stiffnesses, and it was 
found that preservation of the quiescent VIC phenotype was most effective on softer 
hydrogels [79]. Kang et al. studied the effects that modifying different photocrosslinking 
variables, such as photoinitiator concentration and light intensity, had on different valvular 
cell types encapsulated and 3D printed in a mixture of GelMA, PEGDA, and alginate to 
determine the conditions that would optimize cell viability and morphology [210].  Another 
study reported that soft PEG hydrogels (4.3 kPa) could revert VICs from their activated, 
myofibroblastic phenotype into a quiescent phenotype and that the addition of ascorbic 
acid could promote ECM remodeling, including the deposition of collagens I and III, 
without activation of the myofibroblast phenotype [211]. These recent studies have all 
presented the benefits of using soft PEG hydrogels for cell encapsulation in the 
development of healthy valve leaflets as opposed to stiffer materials.  
In addition to obtaining the correct cellular behavior in PEG hydrogel scaffolds, 
several studies have also been conducted regarding the structure and functionality of PEG 
hydrogels in TEHVs. Durst et al. was the first group to study the bending mechanics of 
PEG hydrogels. They conducted three-point bending tests using a custom designed bending 
tester on cell-seeded PEG hydrogels of different concentrations and molecular weights and 
reported the flexural stiffness of these constructs, some of which matched the flexural 
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stiffness of native valve leaflets [212]. Tseng et al. identified the importance of designing 
valve leaflet scaffolds that mimicked the trilayer structure of native leaflets and used the 
mechanical tunability of PEG hydrogels to fabricate quasilaminate gels using a “sandwich” 
layering method [131]. Hockaday et al. also utilized the mechanical tunability of PEG 
hydrogels, as well as a 3D printing technique, to rapidly fabricate mechanically 
heterogeneous aortic valve scaffolds [98]. Jin et al. recognized the importance of patterning 
PEGDA hydrogels in such a way that the anisotropic properties of native leaflets could be 
preserved. This group simulated different patterns of scaffolds created by 
photolithographic patterning in order to guide the design of PEGDA hydrogels to advance 
the structure of TEHVs [213]. The incorporation of anisotropic properties into PEG 
hydrogel scaffolds is currently being improved to better mimic native valve leaflets to 
develop more functional TEHVs.  
 
Hydrolytically biodegradable polymers such as poly(glycolic acid) (PGA), 
poly(lactic acid) (PLA), polycaprolactone (PCL), poly(glycerol sebacate) (PGS), and 
polyurethanes (PU) have shown promise for their use in TEHVs, as they are biocompatible 
and exhibit good mechanical properties suitable for withstanding the stresses and strains 
experienced by valves in a hemodynamic environment. Using techniques such as 
electrospinning, these polymers can be fabricated into fibrous scaffolds similar to native 
valve ECM structure [214]. These materials have been widely studied for TEHVs due to 
these characteristics. PCL will be further discussed in reference to its application to this 





With a lower melting point and a slower rate of degradation in vivo compared to 
PLA, polycaprolactone (PCL) has also been used to contribute mechanical stiffness to 
tissue engineered valve leaflets. PCL is a semicrystalline polymer, highly soluble in 
organic solvents and easy to blend with other polymers [215]. It is commonly synthesized 
by the ring opening polymerization of the cyclic monomer ε-caprolactone [215]. It is elastic 
and has a tensile strength of approximately 23 MPa [216]. These properties make PCL 
suitable for tissue engineering leaflets by methods such as electrospinning or 3D printing. 
However, its slow rate of degradation can be both advantageous and disadvantageous, as 
the scaffold may not be resorbed as new tissue is formed.  
An early study to use PCL as a valve scaffold was conducted by Lieshout et al., in 
which a PCL filament was knitted into round leaflet patches, which were sutured into a 
tube made of the same knitted PCL. The knitted structure was fitted on a mold and a fibrin 
solution was poured over the mold. Once the fibrin gelled, the PCL-fibrin knitted scaffold 
was placed in a pulse duplicator system. While the knitted scaffolds showed complete 
coaptation and durability over 10 million cycles, correct valve function was not obtained 
as there was significant leakage, a backflow 39% of the forward flow, likely due to areas 
of the scaffold where the fibrin detached [217]. Another study compared PCL scaffolds to 
P4HB-coated PGA scaffolds in terms of compaction and degradation over time. 
Rectangular and trileaflet scaffolds of PGA and PCL were fabricated, seeded with human 
and ovine vascular-derived cells, and cultured for 4 weeks. The PCL scaffolds only showed 
up to 10% compaction, whereas the PGA scaffolds showed up to 50% compaction due to 
the quick degradation of PGA in 4 weeks [218]. A similar comparison was conducted 
between these two types of scaffolds in a study of the rate of tissue formation in relation to 
the degradation rate of the scaffold. Seeded and unseeded scaffolds of PGA-P4HB and 
PCL were fabricated and cultured for up to 6 weeks. The scaffold-to-tissue ratio was 
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measured, and uniaxial tensile tests were conducted on these scaffolds each week. From 
this study, they determined that PCL scaffolds resulted in the most tissue formation over 6 
weeks, and the formation of tissue also increased the stiffness of the scaffolds. The tissue 
that formed on PCL scaffolds contained ECM components in amounts similar to those in 
native leaflets [219]. A different study fabricated highly porous PCL scaffolds using a jet-
spraying method to create anisotropic nanofibers and seeded human adipose derived 
stromal cells (hADSC) and human VICs (hVIC) into the anisotropic scaffolds. They found 
that the anisotropic nanofibers caused the cells to develop an elongated morphology 
without causing differentiation of hADSC. The cells also produced ECM, maintained the 
anisotropy, and improved the mechanical properties of the scaffolds over 20 days [129]. 
 
While the field has progressed significantly, a TEHV has yet to be translated into the 
clinic. As highlighted in this review, researchers have access to several different classes of 
biomaterials, each with its own advantages and disadvantages. While fabrication 
techniques have evolved to develop more complex structures closely resembling native 
valves, a main takeaway point is that a single biomaterial may not be sufficient for TEHVs. 
The combination of several biomaterials may be the solution to addressing the limitations 
of using a single biomaterial. The possibility to use several biomaterials with advanced 
fabrication techniques has led to the development of TEHVs using two main approaches, 
an "off-the-shelf" or a patient-specific approach (Figure 7). Both strive to fulfill the 
requirements of an ideal TEHV; however, each approach is unique in the fabrication 
process and the target patient population.  
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Figure 7. There are two main approaches for TEHVs, off-the-shelf and patient-specific.  A-
C) Using the off-the-shelf approach, homologous valves were made from biodegradable 
synthetic materials and homologous cells, followed by 4 weeks of in vitro dynamic strains. 
D-F) Homologous valves were decellularized after culturing. A,D) Represent the 
macrostructure of valve. B,E) Valves after leaflet separation, where the cell-populated 
TEHV experienced tissue retraction. C,F) Valve leaflets after 24 hours of exposure to 
pulmonary conditions. Reproduced with permission [264]. Copyright 2012, Elsevier. G) 
The concept of generating patient-specific heart valve involves autologous cells combined 
with a biomaterial suitable for 3D bioprinting. The scaffold is then maintained or 
conditioned under mechanical stimulus before being transplanted back into the patient. 
Reproduced with permission [2]. Copyright 2015, Elsevier. 
 
An "off-the-shelf" approach involves a scaffold with the ability to remodel and 
form new tissue in the body through its recruitment of endogenous cells. This approach is 
advantageous over the traditional in vitro approach because it does not require 
preconditioning of the scaffold before implantation, which can take up to 6 weeks. During 
this preconditioning time, there are risks of bacterial and fungal contamination. The 



























logistics of maintaining good manufacturing practice and infrastructure for translating an 
in vitro scaffold comes with an enormous cost [220]. 
There are two main methods for developing off-the-shelf TEHVs, in situ heart valve 
scaffolds formed through foreign body reaction, and decellularized TEHVs.  Kishimoto et 
al. developed an autologous heart valve scaffold using in-body tissue architecture 
technology. This involves placing a mold into the subcutaneous space, where the body 
forms a fibrous scaffold surrounding the mold [221]. The stentless mold was tested in a 
goat model, where the valve performed well under systemic circulation. This approach 
enables off-the-shelf scaffolds to be created; however, it is in the initial stages of preclinical 
animal work. More assessment of the immune reaction to a foreign scaffold such as this 
one is needed along with its long-term performance in physiological conditions. 
The concept of decellularized TEHVs was developed, in part, to address the issue 
of cell-mediated contraction observed with cell-populated TEHVs. Decellularization of 
TEHVs involves first creating a biodegradable synthetic scaffold seeded with homologous 
cells. Then scaffolds are subjected to decellularization, in which the process is gentle 
enough to not alter the collagen or tissue structure. Dijkman et al. demonstrated that 
decellularized TEHVs can be stored for up to 18 months without any alterations to the 
tissue structure [222]. In addition, these off-the-shelf scaffolds have the ability to be 
reseeded with stem cells and maintain good cell viability through the crimping process for 
minimally invasive procedures [117]. Following this new approach, researchers 
demonstrated the feasibility and long-term functionality of homologous off-the-shelf 
TEHVs in a sheep and non-human primate model [39, 223].  The concept of off-the-shelf 
TEHVs may be the fastest method to clinical application. While this approach is promising, 
more research is needed on the recellularization, remodeling, and growth potential of off-
the-shelf scaffolds. Concerns with thrombogenicity and calcification long-term will also 
need to be assessed.  
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Other research groups have used hybrid tissue engineering approaches to develop 
off-the-shelf scaffolds with biological and mechanical properties capable of active 
remodeling post-implantation. Janhavi et al. developed a Bio-hybrid valve using 
electrospinning to create aligned nanofibrous scaffolds composed of decellularized bovine 
pericardium and PCL-chitosan. The scaffold was optimized to mimic the anisotropic and 
microstructure properties of native valves. The Bio-hybrid scaffold was 20 times the 
strength of the native valve and demonstrated ECM deposition and cell proliferation when 
seeded with human VICs [224]. While promising, this hybrid TEHV must be evaluated 
under physiological conditions and tested for its regenerative potential.  
In another study, the concept of a biohybrid scaffold capable for eliciting 
endogenous tissue remodeling and repair was developed using rapid manufacturing 
approach. Using jet spinning, a fibrous scaffold of 60/40 ratio of P4HB:gelatin was 
produced using a rapid and automated fabrication technique. JetValves were fabricated in 
less than 15 minutes and demonstrated comparable hydrated shelf-life to fibrin-based 
scaffolds [225]. The JetValve was assessed in vitro and in vivo for its functionality. The 
scaffold demonstrated structural integrity and in vivo, the leaflets demonstrated proper 
coaptation with minor regurgitation [225]. The scaffolds also promoted VIC infiltration, 
but further evaluation is necessary to determine its ability to fully regenerate in vivo. This 
study demonstrates that jet spinning is a fabrication technique that can rapidly generate 
scaffolds of various different diameters. Furthermore, this technique is flexible in that 
growth factors or bioactive molecules can be incorporated into the scaffold to further 
promote endogenous cell and tissue regeneration.  
The off-the-shelf approach using molding and electrospinning has truly advanced 
the potential to translate TEHVs into a clinical viable product. However, the off-the-shelf 
approach may not directly address the need for valves that can undergo somatic growth for 
pediatric patients. Another important aspect to consider is that each individual will have a 
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different endogenous reaction and regeneration to bioactive TEHVs and thus a more 
personalized approach may be necessary.  
 
The patient-specific approach is the concept of generating a scaffold that is specific 
to the recipient of the valve implant, consisting of autologous cells, biomaterials, and an 
anatomical 3D model generated from imaging modalities. The patient-specific approach to 
TEHVs involves the more traditional in vitro method, which can be time-consuming and 
challenging for clinical translation. However, generating a patient-specific valve can have 
significant impact on patients with complications that limit their quality of life, and most 
importantly, younger patients in need of a valve capable of growing and integrating with 
their circulatory system.  
The most relevant method for developing patient-specific TEHVs is the use of 3D 
bioprinting. There are several different methods for 3D bioprinting, such as inkjet, laser-
based, stereolithography, and extrusion-based printing [14, 226]. Each method has 
advantages and disadvantages, but researchers have extensively used extrusion-based 
printing of hydrogels for TEHVs [226]. Often times, computer-aided models can be 
generated using patient CT data to create an anatomical representative implant. With 
advancement in the field of bioprinting, researchers have the ability to control the 
placement of different cell types and biomaterials. This enables complex hybrid scaffolds 
to be generated with anisotropic and heterogeneous properties [98, 106]. These complex, 
patient-specific scaffolds can be fabricated in a record time of less than 45 minutes [98]. 
However, the complexity of 3D bioprinting has led to challenges in identifying a suitable 
set of bioinks that provide good cell viability and mechanical tunability, while having 
shear-thinning and viscous properties to be "printable".  
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While many studies have been able to generate anatomical living conduits, most 
have not been tested in physiological conditions. Another concern with this fabrication 
technique is the resolution needed for constructs to be created. While electrospinning 
enables nanostructures to be tailored, 3D bioprinting is limited to micro-scale printing. 
However, other printing process such as stereolithography can enable higher resolution 
printing, but this process comes with several limitations. This approach does not seem to 
have progressed as rapidly as off-the-shelf approaches mainly because researchers are still 
developing and engineering biomaterials for the 3D bioprinting process. The complexity 
of this multiple variable process is the main cause for the delay in progression of this 
fabrication technique for TEHVs. Similar to the off-the-shelf approach, there are several 
milestones that researchers need to reach before successfully developing a TEHV. The 
ideal TEHV may eventually combine the benefits of both approaches. 
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CHAPTER 4  HUMAN IPSCS-DERIVED MSCS ENCAPSULATED 
IN PEGDA HYDROGELS MATURE INTO VIC-LIKE CELLS ii 
 
Despite recent advances in tissue engineered heart valves (TEHV), a major challenge 
is identifying a cell source for seeding TEHV scaffolds. Native heart valves are durable 
because valve interstitial cells (VICs) maintain tissue homeostasis by synthesizing and 
remodeling the extracellular matrix. In this study, the goal is to demonstrate that induced 
pluripotent stem cells (iPSC)-derived mesenchymal stem cells (iMSCs) can be derived 
from iPSCs using a feeder-free protocol and then further matured into VICs by 
encapsulation within 3D hydrogels. The differentiation efficiency was characterized using 
flow cytometry, immunohistochemistry staining, and trilineage differentiation. Using our 
feeder-free differentiation protocol, iMSCs were differentiated from iPSCs and had 
CD90+, CD44+, CD71+, αSMA+, and CD45- expression. iMSCs underwent trilineage 
differentiation when cultured in induction media for 21 days. iMSCs were encapsulated in 
poly(ethylene glycol) diacrylate (PEGDA) hydrogels, grafted with adhesion peptide 
(RGDS), to promote remodeling and further maturation into VIC-like cells. VIC phenotype 
was assessed by the expression of alpha-smooth muscle actin (αSMA), vimentin, and 
collagen production after 28 days. When MSC-derived cells were encapsulated in PEGDA 
hydrogels that mimic the leaflet modulus, we observed a decrease in αSMA expression and 
increase in vimentin. In addition, iMSCs synthesized collagen type I after 28 days in 3D 
hydrogel culture. Thus, the results from this study suggest that iMSCs may be a promising 
cell source for TEHV.  
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Heart valve disease is an increasing clinical burden associated with high morbidity 
and mortality [14, 16]. The prevalence of valvular disease is expected to triple by 2050 due 
to age-dependent degeneration of heart valves and rheumatic fever in developing countries 
[7, 8]. Congenital heart defects also contribute to the incidence of heart valve disease and 
occur in 1 to 2% of births [227].  
With limited biological diagnostics or drugs to prevent heart valve disease, treatment 
is restricted to valve repair, valve replacement, or the Ross procedure. Valve replacement 
is often performed in older patients using either a mechanical or biological valve prosthesis 
[228]. While these implants improve survival and quality of life, the lack of cells is 
considered to be the main source of failure for mechanical or glutaraldehyde-fixed 
biological valves [10] and the main reason for their inability to grow and repair. Without 
the potential for somatic growth, pediatric patients are required to undergo several surgeries 
for valve refitting [4, 31]. Tissue engineered heart valves (TEHV) can potentially address 
the shortcomings of current implants by incorporating biomaterials with autologous cells 
to enable growth and biological integration [156].   
Native heart valves are durable because valve cells maintain tissue homeostasis [19], 
and without these cells, mechanical or biological prostheses fail over time [10]. Within the 
valve there are two primary cell types: valve endothelial cells (VECs) and valve interstitial 
cells (VICs). The primary focus of this study will be on VICs, which are found throughout 
the three layers of the leaflet and are known to synthesize and remodel the extracellular 
matrix [19, 72, 229]. These cells are believed to mediate long-term valve durability but 
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could play a role in heart valve disease progression [10]. Other cell types such as fibroblasts 
and smooth muscle cells are also believed to populate the leaflets and play a role in active 
matrix remodeling [44].   
Despite recent advances in the field of TEHV, the challenge to identify a suitable cell 
source for seeding 3D scaffolds still remains [10, 44]. To ensure the success of the TEHV, 
various cell types have been investigated. These include xenogeneic, allogenic, and 
autologous cells. Example of these cell types include bone marrow-derived cells, adipose-
derived cells, and amniotic fluid cells from porcine, sheep, and human sources [230-232]. 
Xenogeneic and allogenic cells have been shown to evoke an immune response and may 
only be suitable for preclinical research [14, 233]. Meanwhile, autologous cells are the 
most appropriate cell source for seeding TEHV because they are patient-specific and 
depending on the cell source, they have the potential to be expanded and differentiated into 
other cell types.  
More recently, mesenchymal stem cells (MSCs) derived from various sources such 
as bone marrow (BM) and adipocytes have been investigated as a potential cell source for 
TEHV [44, 95, 234]. This is because of their similar characteristics to smooth muscle cells 
and fibroblasts and their ability to differentiate into several cell types. While initial studies 
demonstrated promising results, a major limitation of MSCs derived from sources like bone 
marrow is a decrease in differentiation potential with expansion of in vitro cultures [235-
237], which results in limited therapeutic efficacy.   
An alternative cell source that maintains a higher level of stemness and can be readily 
expanded for clinical translation is induced pluripotent stem cells (iPSCs). Previous studies 
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have shown that MSCs derived from human embryonic stem cells have the same cell 
surface phenotype compared to BM-derived MSCs [236]. Meanwhile, iPSC-derived MSCs 
(iMSCs) demonstrate trilineage differentiation [238]. With minimal senescence and higher 
telomerase activity potential [236, 239], iMSCs from iPSCs can be a potential cell source 
for TEHV. While only a few other groups have generated iMSCs from iPSCs, there is a 
need for safer transgene-free iPSCs and a feeder-free differentiation protocol for a more 
clinically translatable cell source.  
While the outcomes of a TEHV depends on the cell source, the scaffold in which the 
cells are seeded can be utilized to direct cell phenotype and function. To recapitulate the 
ECM architecture in valve leaflets, a variety of natural and synthetic biomaterials have 
been explored. An ideal scaffold for TEHV is one that provides the biological cues to 
promote cell migration, proliferation, differentiation, and spreading [199]. The scaffold 
should also allow for the exchange of oxygen and cellular waste, and stimulate ECM 
production and remodeling [240].  
In particular, poly(ethylene glycol) hydrogels can be designed to promote proper cell 
phenotype, proliferation, ECM production, and proteolytic degradation of the ECM. The 
goal is to generate a hydrogel that can enable cell adhesion and stimulate iMSCs to actively 
remodel the scaffold with ECM production [10]. Thus, the hydrogel network must 
accommodate the initial activation of iMSCs for active remodeling of the matrix, but over 
time, it must maintain cells in a quiescent fibroblast phenotype to prevent a pathological 
phenotype. Several groups have investigated PEG-diacrylate (PEGDA) as a hydrogel 
scaffold for TEHV applications [33, 204, 212, 241]. Thus, we investigated the maturation 
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of iMSCs into VIC phenotype by encapsulating iMSCs into a 3D PEGDA hydrogel 
mimicking the microenvironment found in native valve leaflets. 
The objective of aim 1 is to develop a feeder-free protocol for differentiating iMSCs 
from integration-free iPSCs and to introduce these cells into a three-dimensional hydrogel 
to promote VIC phenotype and ECM matrix production and remodeling. We hypothesize 
a feeder-free protocol for differentiating embryonic stem cells can be modified to 
differentiate iPSCs into iMSCs. The introduction of iMSCs into a 3D hydrogel commonly 
utilized to study VIC phenotype and ECM production will enable us to identify the 
potential of iMSCs as a cell source for TEHV.  
 
All media components were purchased from Thermo Fisher Scientific (Waltham, MA, 
US) unless otherwise stated.  
 
The differentiation protocol used in this study was modified from a protocol originally 
used to differentiate human embryonic stem cells (hESCs) [242]. The differentiation 
process was modified to be feeder-free. Human integration-free iPSCs (supplementary 
information) were cultured for two passages in mTesR™1 media (StemCell Technologies) 
on Geltrex-coated plates (Gibco) before being harvested for MSC differentiation. Once 
confluent, iPSCs were passaged using collagenase IV at 200 U/mL for 5 minutes at room 
temperature. During differentiation, cells were cultured in differentiation media (DM), 
consisting of knock-out DMEM (KO-DMEM), 0.1 mM β-mercaptoethanol (Sigma 
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Aldrich, MO), 1 mM L-glutamine, 20% fetal bovine serum (GE Healthcare Lifescience, 
UT), 1% non-essential amino acids, and 1% penicillin and streptomycin for 3 days in 
suspension petri dish (Corning, MA) to promote formation of cell aggregates. Afterwards, 
cells were transferred to gelatin-coated plates and cultured for 9 days. When cells became 
confluent, they were passaged by incubating 2 mg/mL of collagenase type II in PBS for 30 
minutes at 37°C. Cells were maintained on gelatin-coated plates, plated at a seeding density 
of 2 x 104/ cm2, and had media changed every 2 to 3 days. After this stage, cell media was 
replaced by iMSC media, which is composed of KO-DMEM, 2 mM L-glutamine, 10% 
fetal bovine serum (GE Healthcare Lifescience, UT), 1% nonessential amino acids, and 
1% penicillin and streptomycin. Media was changed every 2 days. Cell phenotype was 
characterized after the fourth passage. 
 
To characterize MSC surface antigens in iMSCs, cells were harvested, rinsed with 
PBS, and fixed with 4% paraformaldehyde at 0.5 x 106 /mL for 10 minutes at room 
temperature. Afterwards, cells were incubated in 10% goat serum for 10 minutes at room 
temperature. Primary antibodies were diluted in BD Brilliant Flow Buffer and incubated 
for 30 minutes at room temperature. The cells were washed with flow buffer several times 
before being resuspended in 500 µL of flow buffer and analyzed using flow cytometer (BD 
LSR II, BD Bioscience, CA). The conjugated antibodies included mouse anti-human CD90 
BUV395 (1:25, BD Biosciences), rat anti-human CD44 v450 (1:25, Tonbio), and mouse 
anti-human CD45 PE (1:25, Tonbio). For non-conjugated antibodies, rabbit anti-human 
CD71 (1:100, Santa Cruz Biotechnology) and mouse anti-human aSMA (1:100, ABCAM) 
were used. Secondary antibodies included anti-rabbit and anti-mouse Alexa fluorophore 
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488 (1:300, Life Technologies). The panel of markers were controlled by unstained cells, 
human MSCs, and for CD45, a negative marker, fluorescein-5-Maleimide (1mg/mL) was 
used as positive control. For cells that were stained with primary and secondary antibodies, 
a similar protocol for conjugated antibodies was used. However, antibodies were diluted 
in 1% bovine serum albumin (Sigma), and after cells were stained with primary antibodies, 
they were washed several times before incubation in the secondary antibodies for 30 
minutes at room temperature.  
 
To evaluate iMSC trilineage differentiation, cells were harvested and plated in 
triplicates at a seeding density 3.15 x 104 cells/cm2. For adipogenic differentiation, cells 
were cultured in iMSC media until 80-90% confluency, when the media was replaced by 
adipogenic induction media (Amsbio). To differentiate iMSCs into chondrocytes, a 
monolayer differentiation approach was utilized. Once cells reached 100% confluency in 
iMSC media, hMSC chondrogenic media (Vitrobiopharma) supplemented with 10% FBS 
was used. Osteogenic differentiation was conducted with cells at 100% confluency using 
osteoblast differentiation medium (Amsbio). Cells were cultured for 21 days with media 
changes every three days. Caution was necessary to not disturb cell monolayers. All 
differentiation medias were supplemented with 1% penicillin and streptomycin. iMSCs 
maintained in iMSC media during the trilineage protocol was the negative control.  
After differentiation, iMSCs treated with adipogenic and osteogenic induction media 
were fixed with 4% v/v paraformaldehyde in PBS for 10 minutes at room temperature. To 
stain for adipocytes, a working solution of 3 parts Oil Red O (Sigma) stock solution (0.3% 
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w/v of Oil Redo O in isopropanol) with 2 parts DI water was filtered and incubated with 
cells for 5 minutes at room temperature. Multiple wash steps were necessary until washes 
were clear. The nuclei were stained with Hematoxylin following manufacturer’s protocol. 
For staining chondrocytes, toluidine blue stain (Sigma) was used after cells were fixed with 
cold methanol for 2 minutes. Cells were incubated with 0.5% v/v toluidine blue and washed 
with PBS. Cells treated with osteogenic media were stained with 1% w/v Alizarin Red S 
(Ricca Chemical Company) solution for 30 minutes at room temperature in the dark. 
Multiple washes were needed after incubation in the staining solution. Samples were stored 
at -20°C until dye extraction. A microplate reader (BioTek Instruments) was used to 
measure absorbance at 492 nm, 603 nm, and 409 nm for Oil Red O, Toluidine Blue, and 
Alizarin Red S, respectively. Cells were imaged using the Olympus IX71 microscope.  
 
To characterize cell phenotype of iMSCs in comparison to MSCs, cells were cultured 
on glass coverslips for 24 hours at a 2 x 104 cells/cm2 concentration. Immunofluorescence 
staining of aSMA and Phalloidin were performed following standard protocols. iMSCs 
were incubated with primary antibody mouse anti-human aSMA (1:250, Abcam), and 
secondary antibody anti-mouse Alexa Fluor 488 for secondary antibody (1:500). 
Rhodamine phalloidin at 25 µL/mL (Life Technologies) was used to stain for F-actin and 
DAPI (1 µg/mL; Sigma) stained the cell nuclei. For negative controls, only secondary 
antibody was incubated with cells. Cells were fixed with 4% v/v paraformaldehyde for 20 
minutes, permeabilized with 0.2% Triton X-100 followed by 1-hour incubation in 1% BSA, 
all samples were performed at room temperature. The primary and secondary antibodies 
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were incubated overnight at 4°C and 2 hours at room temperature, respectively. Phalloidin 
and DAPI were added to cells for 20 minutes at room temperature. At each step, three 
washes with PBS were performed for 5 minutes each wash. Samples were imaged using 
Olympus IX71 microscope. Human MSCs were used a control cells and all samples were 
conducted as triplicates.  
The ECM component was characterized in 3D PEGDA hydrogels by encapsulating 1 
x 106 cells/mL iMSCs in 5% w/v PEGDA with 5 mM RGDS for 28 days. DAPI was used 
to image cell nuclei and fluorescein-5-Maleimide (10 µg/mL) was utilized to image the cell 
surface. Hydrogels were stained for collagen type I, aSMA, vimentin, periostin, and 
calponin using primary antibodies: mouse anti-human collagen type I (1:100; Abcam), 
mouse anti-human aSMA (1:100; Abcam), rabbit anti-human vimentin (1:100; Santa 
Cruz), rabbit anti-periostin (1:100; Abcam), and mouse anti-calponin (1:100; Abcam). The 
following secondary antibodies were used: goat anti-mouse Alexa Fluor 647 conjugate 
(1:200), and goat anti-mouse Alexa Fluor 488 (1:200). The protocol mentioned above for 
2D cell culture was utilized for cell-laden hydrogels. iMSCs characterization was 
performed using an Olympus IX81 for confocal microscope imaging. To control for 
immunostaining, PEGDA blank hydrogels and secondary only antibody stained cell-laden 
hydrogels were used. Primary VICs (DV Biologics) and human dermal fibroblasts (HDFs) 
were utilized as a phenotype control. The level of fluorescence was quantified using 
ImageJ. First, a threshold was applied to images and then, using particle analysis function 




Poly(ethylene glycol) diacrylate (PEGDA; ESI BIO) of molecular weight 3400 Da 
was used to make hydrogels. A prepolymer solution of 5% w/v PEGDA, 10 µM Eosin Y 
(Santa Cruz Biotechnology), 0.375% v/v 1-vinyl-2-pyrrolidinone (NVP; Sigma), 1.5% v/v 
triethanolamine (TEOA; Sigma) was crosslinked using a white-light source (LED Light; 
Braintree Scientific, Inc.) for 1 minute. Hydrogels were soaked in PBS and then in media. 
Hydrogels with no cells were used for mechanical tests.  
Hydrogel functionalization was performed by conjugating Arg-Gly-Asp-Ser 
(RGDS) peptide (Cayman Chemical, MI) to acrylate-PEG-succinimidyl valeric acid 
(ACR-PEG-SVA; Laysan Bio, Inc., AL) in 50 mM sodium bicarbonate buffer solution at 
pH 8.5 (Sigma). RGDS peptide was incorporated into the PEG mesh network to enable cell 
adhesion. ACR-PEG-SVA was combined with RGDS at a 1:1.2 molar ratio (ACRY-PEG-
SVA: RGDS) and reacted overnight at room temperature under constant agitation. PEG-
RGDS was then dialyzed with MWCO membrane 3400 against 4 L of ultrapure water for 
3 days with 4-5 water changes per day. Samples were then lyophilized into a dry powder. 
Conjugation was confirmed using NMR and MALDI-TOF. 
To create cell-laden PEGDA hydrogels, a prepolymer solution of 5% w/v PEGDA 
with the white-light crosslinking components stated above was sterile-filtered using a 0.22-
um syringe filter (EMD Millipore). Cells were then added to the prepolymer solution at 1.0 
x 106 cells/mL (cell viability and mechanical testing) or 1.5 x 106 cells/mL (ECM 
production studies). To generate hydrogel disks, 15 µL of prepolymer solution was injected 
into molds consisting of a SigmaCote glass slide (Sigma), silicone spacers of 0.381 mm 
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thickness (McMaster-Carr), and an 18-mm round coverslip (Fisherbrand). The prepolymer 
solution was crosslinked under LED white-light (Braintree Scientific) for 1 minute and 
gels were then soaked in PBS, followed by iMSC media. The media was changed every 2 
days.   
 
The overall properties of PEGDA hydrogels was characterized by compression testing 
using a TA Instruments ElectroForce 3100 Mini. Before performing compression testing, 
hydrogels were soaked in PBS for at least 24 hours and the diameter of each hydrogel was 
measured using a caliper. The thickness of the hydrogels was about 0.85 mm. Quasi-static 
compression testing was performed on a group of hydrogels, sample size n = 8, with a 1 N 
load and maximum displacement of 0.4 mm at a rate of 0.02 mm/sec. The linear portion of 
the stress-strain curve between 5-15% strain was used to calculate the least-squares fit slope 
to determine Young’s modulus.  
 
To determine cell viability, cell-laden hydrogels were stained with Live/Dead™ assay 
with calcein-AM and ethidium homodimer at 4 µM and 2 µM concentrations, respectively. 
Both components of Live/Dead™ assay were diluted in DAPI solution and incubated with 
hydrogels at 37°C for 20 minutes before imaging. Cell viability was measured at day 1 and 
day 7. Confocal microscopy (Olympus IX81) and ImageJ software was used to image 
hydrogels and quantify cell viability, respectively.  
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Before digestion of hydrogels, each construct was weighed, and excess water was 
removed by using weighing paper. PBE buffer was prepared by weighing out 7.1 g 
Na2HPO4 and 1.86 g Na2EDTA in 500 mL of ddH2O and pH corrected to 6.5. The solution 
was sterile-filtered with a 0.22 um filter before use. Constructs were digested and 
homogenized in a papainase solution composed of 1.67 mg per mL of L-Cysteine (Sigma-
Aldrich), PBE buffer, and 0.5% v/v papain (Sigma-Aldrich). Samples were incubated in 
this solution for 15-18 hours at 60°C. Samples were then frozen at -20°C until analysis. 
The cell density in each construct was quantified using the Quant-iT™ PicoGreen® assay 
following manufacturer’s instructions.  
To determine collagen content, samples were first homogenized in ultra-pure water 
and then equal volume of 10N HCl was added to a glass PTFE-lined vial. Samples were 
hydrolyzed for 3 hours at 120°C. Once cooled, 5 mg of activated charcoal was added to 
samples. The supernatant was recovered by centrifugation. Samples were stored at -20°C 
until analysis. Using the manufacturer’s instruction for the hydroxyproline assay (Sigma-
Aldrich), samples were mixed with Chloramine T/Oxidation buffer and diluted DMAB 
reagent. Samples were incubated in these two components for 90 minutes at 60°C before 
absorbance was recorded at 560 nm. Data was normalized to the wet weight of the 
hydrogel.  
 
All quantitative data was expressed as the mean ± standard deviation (SD). Statistical 
analysis was performed using Graphpad Prism 7 (La Jolla, CA). One-way ANOVA with 
post-hoc Tukey-Kramer test was used to determine statistical significance in flow 
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cytometry experiments for surface marker expression. Student t-tests were utilized for 
statistical analysis of absorbance levels in trilineage differentiation and cell viability assays 
and for marker quantifications. A one-way ANOVA with post-hoc Dunnett's test was 
performed for collagen production. Sample size was determined by preliminary data and a 
Monte-Carlo simulation using Prism 7. In general, sample size n = 3-5 and technical 
replicates were used. Statistical significance was considered at a value of p < 0.05. 
 
 
 To address the need for a suitable cell source for seeding TEHVs, integration-free 
iPSCs were first generated from human dermal fibroblasts derived from a healthy child 
(Supplementary Figure 28), then differentiated into iMSCs using a feeder-free protocol. 
The surface marker profile of iMSCs was characterized by the expressions of CD90, CD44, 
CD71, aSMA, and CD45 using flow cytometry. Figure 8 shows that iMSCs have a 99.3%, 
98.8%, 99.6%, and 95.9% positive expression of CD90, CD44, CD71, and aSMA, 
respectively. Meanwhile, there was a 0.020% expression of CD45, a hematopoietic marker. 
The expression of CD90+, CD44+, CD71+, aSMA+, CD45- phenotype suggests that iMSCs 
have a similar surface marker profile to MSCs.  
 In addition to surface marker analysis, cells were cultured in adipogenic, 
chondrogenic, and osteogenic induction media to verify their multipotency. After 21 days 
in induction media, iMSCs demonstrated the capability to undergo trilineage 
differentiation (Figure 9). iMSCs cultured in adipogenic induction media led to 
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intracellular lipid vesicles stained by Oil Red O dye. The levels of Oil Red O staining were 
quantified by measuring the absorbency at 492 nm. iMSCs treated with induction media 
resulted in a significantly higher absorbency of the dye compared to cells in MSC media. 
 
Figure 8. Characterization of iMSCs differentiation efficiency via flow cytometry.  A) 
iMSCs were stained for positive expression of CD90, CD44, CD71, and αSMA surface 
markers. No expression of CD45 was observed. Blue peaks - stained cells. Black peaks - 
unstained cells. B) The expression of each marker was quantified by gating population of 
iMSCs and comparing to non-stained cells. N = 3-4. 
Furthermore, iMSCs cultured in osteogenic media led to statistically higher levels of 
extracellular calcium deposits, stained bright red using Alizarin Red S, as compared to cells 
in MSC media. Meanwhile, iMSCs cultured in chondrogenic induction media began to 
form aggregates that stained purple-blue with toluidine blue stain, suggesting that iMSCs 
have differentiated into chondrocytes. The measured absorbency of toluidine blue dye was 
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also statistically higher than cells without induction media.  
 Furthermore, immunocytochemical staining was used to assess the localization of 
marker proteins aSMA and F-actin in iMSCs compared to control, human MSCs. Figure 
10 shows iMSCs have stress fibers of aSMA and F-actin similar to human MSC controls. 
The cell morphology is also observed to be similar between iMSCs and human MSCs, 
where cells are fibroblast-like, bipolar, and elongated.  
Figure 9. Trilineage Differentiation of iMSCs. A) iMSCs were cultured in adipogenic, 
osteogenic, chondrogenic induction media for 21 days. Control iMSCs were cultured in 
MSC media. iMSCs demonstrate the ability to differentiate into adipocytes by evidence of 
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intracellular fat deposits stained by Oil Red O. iMSCs cultured in osteogenic media led to 
high levels of extracellular calcium deposition stained in bright red using Alizarin Red S. 
High levels of toluidine blue staining in observed in iMSCs treated with chondrogenic 
media. B) The absorbency of each stain was quantified. *p<0.05; **p<0.01; ***p<0.001; 
t-test. Scale bar 50 μm. 
Figure 10. Characterization of iMSC phenotype.  iMSCs and human MSCs (control) were 
immunostained with DAPI, F-Actin, and αSMA after 24 hours. iMSCs had comparable 
expression of αSMA and F-actin stress fibers to human MSCs. Scale bar 50 μm. 
 
 Before encapsulating iMSCs in PEGDA hydrogels, RGDS, an adhesion peptide 
sequence, was conjugated to acrylate-PEG-succinimidyl valerate (SVA) with a molecular 
weight of 3.5 kDa using an established protocol [243]. This peptide sequence is conserved 
in fibronectin, an extracellular matrix protein that enables cellular interaction through 
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integrin binding. The 1H NMR spectra in (Supplementary Figure 29) demonstrates that 
RGDS was conjugated to PEG via peaks at 4.4 nm, 4.2 nm, and 3.10 ppm. The conjugation 
was also verified by a shift in mass, 3673 Da for the acrylate-PEG-SVA to 3956 Da for 
PEG-RGDS, using MALDI-TOF (Supplementary Figure 30).  
 To determine the PEGDA hydrogel properties, PEGDA hydrogels with and without 
iMSCs were characterized through compression testing. Using the molds described under 
the methods section, PEGDA hydrogel discs of 5% w/v ratio following 1-minute of white-
light exposure were created. Compression testing demonstrated the average modulus of 
PEGDA hydrogels at 1-minute white-light exposure to be 5.6 kPa (Figure 11). Meanwhile, 
cell-laden hydrogels had a significantly higher modulus of 30 kPa, and after 28 days of 
encapsulation, there was a significant decrease to 3.7 kPa. The overall modulus of blank 
PEGDA and 28 day hydrogels were still within the modulus of leaflet layers (~5-13 kPa) 
that native valve cells experience [125].   
 
Figure 11. Mechanical properties of PEGDA hydrogels.  Compression testing was used to 
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determine the bulk modulus of 5% v/w PEGDA hydrogels with 5mM RGDS, crosslinked 
with white-light for 1- minute. The elastic modulus in PEGDA only hydrogels was an 
average of 5.6 kPa. While cell-laden PEGDA hydrogels had a modulus of 30 kPa, which 
decreased to 3.7 kPa after 28 days. One-way ANOVA. ****p<0.0001; N = 8 -10. 
 
The cell viability of iMSCs encapsulated in 5% v/w PEGDA hydrogels with 5 mM 
RGDS was assessed after 1 and 7 days using the Live/Dead assay. After 1 day of 
encapsulation, iMSCs remained viable at 93% with a round cell morphology (Figure 12). 
Meanwhile, the cell viability decreased to 77% at day 7, though this was not statistically 
significant. In addition, there was a noticeable difference in cell morphology when iMSCs 
were encapsulated within the hydrogel or near hydrogel surface at day 7 as shown by 
calcein AM staining. Near the surface of the hydrogel, the cells showed signs of spreading 





Figure 12. Cell viability of iMSCs encapsulated in 5% PEGDA hydrogels. iMSCs were 
encapsulated into PEGDA hydrogels 5% w/v with 5 mM RGDS. Hydrogels were cultured 
for 1 or 7 days. Cell viability was 93% after 1 day of encapsulation and maintained at 77% 
after 7 days. There was no statistical significance between day 1 or day 7. Green is Calcein 







To assess iMSCs maturation into VIC-like cells, iMSCs were encapsulated in 5% 
w/v PEGDA hydrogels with 5 mM RGDS. Primary VICs and HDFs were also encapsulated 
into PEGDA as phenotype controls. As shown in Figure 13, cells within hydrogels were 
stained for aSMA and vimentin at 1- and 28-days post-encapsulation. At day 1, diffuse 
staining of aSMA (red) with no distinct stress fibers or staining for vimentin (green) was 
observed. At day 28 post-seeding, there was a distinct difference in staining patterns of 
aSMA and vimentin compared to day 1, where there was significantly less diffuse staining 
Figure 13. iMSC expression of αSMA and vimentin after 28 days. iMSCs, VICs, and HDFs 
were encapsulated into PEGDA hydrogels 5% w/v with 5 mM RGDS for 28 days. 
Fluorescence for αSMA and vimentin was quantified for each cell type at day 1 and day 28.  
Student t-test was conducted to comparing day 1 to day 28. DAPI - Blue; Vimentin - Green; 
αSMA - Red. **p<0.01; ***p<0.001; t-test; N = 4-8. Scale bar 50 μm. 
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of aSMA and more staining for vimentin. In comparison, primary VICs and HDFs had 
higher expression of aSMA at day 1, followed by a decrease in expression by day 28. 
When the levels of aSMA and vimentin were compared at day 28 between the three cell 
types, iMSCs expression of aSMA and vimentin were most similar to VICs 
(Supplementary Figure 32).  
 To further examine VIC-like differentiation, gels were stained with both calponin 
and periostin.  While quantitative analysis of iMSCs showed that there was a small decrease 
in these 2 markers from day 1 to day 28, this was not statistically significant (Figure 14). 
VICs had a significant increase in periostin over time, while calponin remained at a similar 
level throughout the experiment. Meanwhile, HDFs showed no changes in either marker 
over time (Figure 14). When the levels of expression for periostin and calponin were 
compared at day 28 for all 3 cell types, iMSCs had similar levels of expression of periostin 
compared to VICs and HDFs; however, the level of calponin was significantly reduced 








 To determine if matured iMSCs had the capacity to deposit collagen, an important 
ECM component necessary to maintain valve homeostasis, hydrogels were fluorescently 
stained for collagen type I overlaid with the cell membrane (Figure 15). When iMSCs were 
initially encapsulated, there was minimal intracellular staining of collagen and some 
collagen deposits at the edge of the cell membrane. At the subsequent time point, collagen 
deposition surrounded the cell membrane as observed by the extracellular red staining. 
Figure 14. iMSC expression of periostin and calponin after 28 days.  All three cell types, 
iMSCs, VICs, and HDFs were encapsulated into 5% w/v PEGDA hydrogels with 5 mM 
RGDS for 28 days. Fluorescence for periostin and calponin was quantified for each cell type 
at day 1 and day 28.  Student t-test was conducted to compare changes in expression over 
time. DAPI - Blue; Periostin - Green; Calponin - Red. **p<0.01; t-test; N = 4-8. Scale bar 
50 μm. 
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Quantitative analysis of collagen staining was significantly increased at day 28 compared 
to day 1. Meanwhile, there was no change in collagen production in either VIC or HDF 
hydrogels.  When all 3 cell types were compared at day 28, iMSCs had significantly higher 
levels of collagen type I staining when compared to VICs and HDFs (Supplementary 
Figure 31).  
Figure 15. iMSC Collagen Type I Deposition in PEGDA Hydrogels. iMSCs, VICs, 
and HDFs were encapsulated into PEGDA hydrogels 5% w/v with 5 mM RGDS. 
Hydrogels were cultured for 1 and 28 days before being stained for collagen type 
I. Over time, iMSCs begin to deposit collagen.  Student t-test was conducted to 
compare changes in expression over time. DAPI - Blue. Cell membrane - Green. 
Collagen type I - Red. ****p<0.0001 t-test; N = 3. Scale bar 50 μm. 
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 In separate experiments, the amount of collagen was quantitatively measured using 
the hydroxyproline assay, as hydroxyproline is a major component of collagen that 
stabilizes the helical structure (Figure 16). To control for changes in cell viability and/or 
number, total DNA was measured using Quant-iT™ PicoGreen® and used for 
normalization. While there was no significant change in DNA content with time, there was 
a statistically significant increase in normalized collagen deposition in day 28 hydrogels 
compared to day 1. However, no statistical difference was detected between day 1, 7, and 
14 days.  
 
 
 A major shortcoming for current valve prostheses is the absence of cells required for 
active repair and remodeling of the scaffold [10]. Valve cells play an important role in the 
tissue homeostasis, in particular VICs, which synthesize and remodel the extracellular 
Figure 16. Quantification of DNA content and collagen in cell-laden PEGDA hydrogels. 
iMSCs were encapsulated into 5% w/v PEGDA hydrogels with 5 mM RGDS for 1, 7, 14, 
and 28 days. A) Using the PicoGreen assay, the DNA content remained unchanged at all 
time points. N = 4. B) Collagen content was determined by hydroxyproline assay and 
normalized by wet weight of hydrogel. *p<0.05 vs day 1; ANOVA followed by Dunnett’s 
post-test. N = 4-5. 
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matrix [19, 72, 229]. In aim 1, we attempted to generate a patient-specific cell source for 
adequate seeding of TEHVs. Cells were generated using a feeder-free differentiation 
protocol that had been previously used for embryonic stem cell differentiation [244], in 
order to differentiate induced-pluripotent stem cells (iPSCs) into iPSC-derived 
mesenchymal stem cells (iMSCs). iMSCs had similar expression in surface markers, 
phenotype, and functionality to adult human MSCs. These iMSCs were capable of 
trilineage differentiation as shown via staining and quantitative assays, and when cultured 
in a PEG hydrogel, differentiated further in to a VIC-like phenotype.  
 The advantage of using MSCs derived from integration-free iPSCs is the reduced risk 
associated with genome-integrating viruses [245]. Other protocols using iPSCs to derive 
iMSCs, use genome integrating viral vectors [246], which pose the risk of mutations that 
can alter differentiation potential and tumorigenesis, often caused by c-Myc oncogene 
reactivation [247]. Furthermore, using iPSCs as the main source for iMSCs presents the 
opportunity to differentiate iPSCs into other cell types from the germ layers: ectoderm, 
mesoderm, and endoderm. iMSC derived from iPSC has the ability to expand indefinitely 
without senescence and to differentiate into different cell types such as chondrocytes, 
osteoblasts, adipocytes, smooth muscle cells  [238, 248]. In contrast, MSCs derived from 
sources like bone-marrow have limited differentiation potential and capabilities after 
extended in vitro culture [236, 237]. Thus, the feeder-free protocol and integration-free 
iPSCs reported here, presents advantages such as the inexhaustible autologous cell source, 
potential differentiation into several cells types, and the reduced risk for carcinogenicity 
compared to other protocols [236, 239, 248, 249]. 
 After generating iMSCs, we hypothesized that introducing iMSCs into a 3D culture 
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decorated with RGDS, an adhesion peptide, would promote cells to mature into VIC-like 
phenotype. A previous study by Zhang et al. demonstrated that RGDS concentration can 
regulate VIC phenotype [33]. Furthermore, VICs encapsulated within degradable PEG-
RGDS hydrogels for 21 days produced ECM such as fibronectin and collagen type I, 
suggesting that RGDS is an important peptide for regulating and promoting VIC phenotype 
and ECM production [33]. Before encapsulating iMSCs, we first characterized the 
properties of the PEGDA hydrogels to verify that it closely mimicked the 
microenvironment in native valve leaflets. Using compression testing, the Young's 
modulus of PEGDA blank hydrogels was within the physiological modulus of 5-13 kPa 
[125], interestingly there was an increase in modulus after cell encapsulation. A possible 
reason for a 6-fold increase could be due to the formation of a denser polymer network 
surrounding cells. To assess this, a hydrogel swelling test and scanning electron 
microscopy (SEM) can be used to assess the changes in the polymer crosslinking such as 
the mesh size. After 28 days, the modulus decreased either because of non-enzymatic 
degradation of PEGDA or cell death.  Based on previous studies the modulus of heart valve 
leaflets is estimated to about 2 MPa and 15 MPa in the radial and circumferential direction, 
respectively [250, 251]. While this is several orders of magnitude higher than our study, 
the hydrogels utilized here were not intended to replicate the overall leaflet modulus but 
rather the microenvironment in which the valve cells experience.  
 The viability of iMSCs was characterized using Live/Dead assay. iMSCs 
encapsulated into PEGDA hydrogels demonstrated over 93% cell viability after day 1, this 
value then decreased to about 77% after 7 days in culture. A possible reason for the 
decrease in cell viability is the exposure to free radical from the polymerization process 
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[252]. Furthermore, there was a distinct difference between cells on the surface compared 
to those encapsulated in the hydrogel. This difference can be explained by the fact that 
iMSCs may have been unable to spread through a non-degradable hydrogel, resulting in a 
round morphology. Thus, we also created a hydrogel containing a slow-degrading PEG-
LGPA-PEG sequence (MALDI-TOF shown in Supplementary Figure 31)  [253], iMSCs 
did not assume a spindle-like morphology but rather formed large aggregates of cells, either 
through proliferation or migration, both of which are not favorable for a tissue engineered 
heart valve scaffold (Supplementary Figure 32,Figure 33,Figure 34,Figure 35). The LGPA 
linker was chosen due to slower degradation kinetics as linkers such as GPQ degrade on 
the order of days and were likely unfavorable. Additionally, we examined the mechanical 
properties of the degradable hydrogel (Supplementary Figure 36) and found that these 
hydrogels at baseline were much softer than non-degradable hydrogels. Thus, future studies 
will examine degradation linkers of different rates or a combination of degradable natural 
polymers, to generate a more suitable 3D environment for iMSCs to spread and mature into 
VICs.  
 VICs are known to be a heterogeneous cell population with various sub-phenotypes 
that can resemble fibroblasts, smooth muscle cells, and MSCs [19, 48, 72]. Previous studies 
have demonstrated that VICs can be categorized into several phenotypes such as embryonic 
progenitor MSCs, quiescent VICs, activated VICs, progenitor VICs, and osteoblastic VICs 
[48]. The ideal phenotype for TEHVs is one that can be initially activated to remodel the 
scaffold and then transition into a quiescent phenotype, where cells maintain the scaffold 
structure. If VICs remain in an activated state, there could be issues with scaffold 
contraction and potential transdifferentiation of VICs into osteoblast-like cells [73, 254].  
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 Activated VICs demonstrate high levels of aSMA with distinct fiber formation, 
which in our study was observed in the 2D culture when immunostaining for aSMA and 
F-actin and comparing it to human MSCs. At the initial encapsulation of iMSCs into 3D 
PEGDA hydrogels, there was diffuse staining of aSMA with no staining of vimentin 
present at day 1. There was a significant decrease in aSMA expression thereafter, and the 
staining transitioned from diffuse to punctate staining of aSMA after 28 days. The decrease 
in aSMA was accompanied by an increase in vimentin and low levels of periostin and 
calponin expression. Periostin is a protein involved in cell adhesion and robustly expressed 
in cardiac fibroblasts [255], and calponin is a calcium binding protein often found in 
smooth muscle cells or myofibroblast-like cells [256] and thus low levels of these proteins 
is desirable.  These results suggest that by introducing iMSCs into a 3D hydrogel system, 
iMSCs express less aSMA, more of vimentin, and low levels of periostin and calponin. 
This can be interpreted as cells are transitioning from an activated phenotype to a more 
quiescent phenotype, which is characterized by the expression of vimentin, a marker for 
fibroblasts [44, 48].  
 To determine whether iMSCs are more VIC-like or fibroblast-like, the expression of 
aSMA, vimentin, periostin, and calponin was compared to VICs and HDFs after 28 days 
of encapsulation (Supplementary Figure 32).  iMSCs had similar expression of aSMA, 
vimentin, periostin markers compared to VICs. The only significant difference in marker 
expression was calponin, which was higher in VICs. Although, the iMSCs were not 
identical to VICs, they may not need to be as VICs are heterogeneous in nature [257]. 
Furthermore, a previous study demonstrated that it was feasible to use MSCs as a cells 
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source for heart valve tissue engineering [110]. The results of that study showed MSCs 
having comparable levels of collagen,  aSMA, and vimentin when introduced to different 
scaffolds [110].    
 While iMSCs appear to transition into a quiescent phenotype, it is important to 
discuss some of the limitations of the current hydrogel platform that could be resulting in 
the observed phenotype. iMSCs were cultured in non-degrading PEGDA hydrogels, which 
can result in a round-like morphology and "quiescent" state mainly because cells are unable 
to spread and degrade the hydrogel. However, when iMSCs were introduced into a slow-
degrading PEGDA hydrogel cells did not spread throughout the hydrogel but rather formed 
aggregates of cells after 28 days of encapsulation (Supplementary Figure 33, Figure 34, 
Figure 35). In fact, the decrease in aSMA and increase in vimentin was not observed in the 
slow-degrading PEGDA hydrogels, further suggesting that the non-degrading hydrogel 
may be the more ideal environment for iMSCs to transition into a quiescent phenotype and 
produce collagen type I. 
 Collagen is a major extracellular matrix component that makes up the valve leaflet, 
along with proteoglycans and elastin [138]. Using immunostaining of iMSCs within 
hydrogels, there was little evidence of collagen type I at day 1, and as time progressed, 
collagen deposition significantly increased and was localized surrounding the cells. When 
compared to VICs and HDFs, iMSCs had significantly higher levels of collagen (Figure 
32). Quantitative hydroxyproline assay confirmed the immunostaining of collagen as there 
was significant increase at 28 days compared to day 1. Interestingly, while DNA levels 
rose progressively during the interim time points, it was not statistically significant. Again, 
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similar to above, this could be due to the fact that the cells were unable to degrade the 
hydrogel and thus replace it with their own matrix, or that specific signals need to be added 
to the hydrogel to induce matrix secretion. Another explanation for an increase in DNA 
content at day 28 is that cells could have been in a "recovery state" post-encapsulation and 
only after 28 days were cells able to proliferate and produce collagen. However, a limitation 
of this study is that cells from the surface were not removed before homogenization. 
Overall, these findings suggest that iMSCs have the capacity to synthesize collagen type I 
when introduced into a 3D microenvironment mimicking the valve leaflet layers. 
 In future studies, we plan to investigate the potential for iMSCs to produce 
proteoglycans, elastin, and secrete matrix metalloproteinases. The use of PEGDA is to 
demonstrate, that as a simplified model, iMSCs can progress towards a VIC-like 
phenotype. However, further work is necessary to study these cells long-term as a potential 
cell source for tissue engineering. The role of mechanical stimuli is also worth investigating 
as it is a known to impact VICs phenotype and function [19].  
 
 Developing a suitable cell source for tissue engineering is a critical component for 
the success and durability of TEHVs. In this study, we attempt to address this problem by 
differentiating iMSCs from iPSCs and then further maturing these cells into VIC-like cells 
by introducing these to a 3D culture designed to mimic the layers of the valve leaflets. 
First, a modified differentiation protocol was utilized to differentiate into iMSCs using a 
feeder-free approach. Next, the PEGDA hydrogel was characterized and tuned to match 
the mechanical properties observed in valve leaflets. iMSCs were then encapsulated into 
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PEGDA hydrogels to study the effects of a 3D culture in the maturation of iMSCs into 
VIC-like cells. Encapsulated iMSCs demonstrated a transition from an activated VIC-like 
phenotype to a more quiescent state. In addition, collagen deposition was identified in cell-
laden PEGDA hydrogels, corresponding to the potential use of iMSCs as a cell source for 
TEHV. As such, these experiments contribute a potential new cell source for seeding 
TEHVs as well as highlight the importance of a 3D culture environment to influence cell 









CHAPTER 5  A MULTILAYERED VALVE LEAFLET 
DEVELOPED FROM PCL AND GELMA/PEGDA HYDROGEL 
 
For children with heart valve disease, valve replacement is often the only possible 
treatment. However, valve implants are incapable of growth, so multiple surgeries are often 
needed for valve refitting. Patient-specific, tissue engineered heart valves (TEHV) may 
address this issue, but mechanically functional TEHVs have yet to be developed. This study 
aims to recreate native valve structure using PCL and cell-laden GelMA/PEGDA hydrogels 
in order to generate a valve scaffold capable of growth and regeneration while maintaining 
proper valve function. Two main layers (fibrosa and spongiosa/ventricularis) were 
developed individually before being combined and evaluated together. The PCL fibrosa 
layer was 3D printed to be 40-50 µm thick with circumferential, radial, and diagonal strand 
alignments. These scaffolds were evaluated for their mechanical properties, degradation 
over time, and their compatibility with iMSCs. Uniaxial testing indicated anisotropy can 
be accomplished via strand orientation and under physiological conditions, there was 
evidence of initial degradation of these scaffolds over 8 months. Immunostaining also 
indicated that iMSCs on PCL scaffolds treated with poly(methacrylic acid) (PMAA) begin 
to transition toward a more VIC-like phenotype. Next, a combination of 7.5% w/v GelMA 
and 5% w/v PEGDA was used to encapsulate iMSCs within a hydrogel 
spongiosa/ventricularis layer. Cell-laden hydrogels were mechanically evaluated for 
degradation and assessed for survival within the hydrogel. While cell-laden hydrogels were 
significantly lower in storage and loss moduli compared to blank hydrogels, they did not 
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exhibit a change in moduli over 28 days, indicating that the hydrogels were not undergoing 
short-term degradation. Cells encapsulated within the hydrogel remained 80% viable after 
day 7. To combine the layers, the hydrogel layer was crosslinked onto treated PCL 
scaffolds. These scaffolds were assessed under aortic pulsatile shear stress conditions, and 
iMSC expression of VIC markers, as well as production of collagen type I, was quantified 
by immunostaining. These results indicated that pulsatile shear stress did not induce a VIC-
like phenotype. However, encapsulated cells did begin to deposit collagen I.		
 
An estimated two to three million children live with heart disease, about 5% of whom 
have heart valve disease [4-6]. This is mainly due to congenital heart defects in 
industrialized countries and the persistence of rheumatic fever in underdeveloped regions 
[7-9]. Valve disease is treated by replacement or valve repair. In most cases, valve repair 
is not possible, and valve implants have a number of risks, such as thrombogenicity and 
calcification. A significant issue for pediatric patients is the lack of small implants capable 
of growing, often requiring several surgical interventions for valve refitting [4, 10]. Tissue 
engineered heart valves (TEHVs) have the potential to address limitations with current 
implants through their self-repairing and remodeling capacity.  
Although there have been recent advancements in the field of TEHVs, the challenge 
to develop a mechanically functional aortic TEHV for long-term implantation remains. 
Ideally, a TEHV should be biocompatible, durable, and anti-thrombogenic, while 
exhibiting physiological hemodynamic profile. A TEHV that meets all these criteria and is 
capable of functioning under physiological aortic conditions has not yet been created.  
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The aortic heart valve opens and closes approximately 4 million times a year, with 
minimal transvalvular pressure gradient [10]. The mechanical strength of valves is 
attributed to the unique microstructure of each leaflet layer. The orientation of ECM of 
these layers are believed to enable the constant loading and unloading of the valve leaflets 
[19]. A challenge with tissue engineering an aortic valve is the difficulty to replicate the 
trilayer leaflet structure, which is comprised of the fibrosa, spongiosa, and ventricularis 
[10, 41, 120]. The fibrosa provides mechanical strength through circumferentially aligned 
collagen fibers. The spongiosa is the middle layer, rich in glycosaminoglycans, while the 
ventricularis is composed of radially aligned elastin. The leaflet layers are surrounded by 
valvular interstitial cells (VICs) that maintain tissue homeostasis of the valve [19]. With 
the native valve leaflet structure and function as a guide, the goal is to design a scaffold 
that closely mimics this structure to develop a functional aortic TEHV. 
To develop a TEHV, the biomaterials and the approach used is vital to ensure a 
mechanically functional heart valve. The biomaterial requirements for our TEHV are the 
ability to integrate cells and promote physiological phenotype and cellular function, 
compatibility with 3D bioprinting, tunable mechanical properties, and most importantly, 
undergo slow degradation over time. Considering these requirements, we have opted for 
two types of biomaterials: biodegradable poly-e-caprolactone and a formulation of gelatin 
methacrylate and polyethylene diacrylate. The combination of these two types of 
biomaterials is hypothesized to enable us to incorporate cells into the leaflet scaffold and 
replicate the microstructure of the leaflet layers using 3D printing. Furthermore, since the 
geometry and design are key components for a functional TEHV, 3D bioprinting and 
molding will be the primary approach used. 
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While other methods have been used to generate heart valve conduits, these 
approaches have been limiting in their ability to incorporate different materials in 
customized patterns while enabling spatial placement of cells. Another major advantage of 
3D printing is the ability to easily generate patient-specific valves of different geometries 
and sizes. The concept of using 3D bioprinting to generate a TEHV has been tested by 
various other groups [14, 106]; however, the combination of the proposed biomaterials, 
geometry, and valve design has not yet been investigated.  
The objective of aim 2 is to develop a multilayered valve leaflet using PCL and a 
hydrogel-based bioink to generate a mechanically functional aortic TEHV that has the 
ability to promote VIC-like phenotype, ECM matrix production, as well as undergo slow 
degradation. We hypothesize that a leaflet composed of 3D printed PCL and a hydrogel 
layer can be combined in a specific spatial orientation to recapitulate the ECM orientation 
observed in native leaflets, and that under physiological shear conditions, leaflets will have 
positive expression of VIC markers and demonstrate initial ECM production.  
 
All media components were purchased from Thermo Fisher Scientific unless otherwise 
stated.  
 
Human induced mesenchymal stem cells (iMSCs) derived from a feeder-free induced 
pluripotent stem cell protocol were used for experiments [11]. Cells were maintained in 
iMSC media containing KO-DMEM, 2mM L-glutamine, 10% fetal bovine serum (Atlanta 
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Biologics), 1% nonessential amino acids, and 1% penicillin and streptomycin. The media 
was changed every 2 days.  
 
For this study, poly-e-caprolactone (PCL; Sigma-Aldrich) of molecular weight of 
80,000 Da was used. Scaffolds were 3D printed to a thickness of 40-50 µm using the 
EnvisionTEC 3D Bioplotter (Gladbeck, Germany). PCL pellets were first melted in the 
high temperature cartridge to 180°C for 20-30 minutes before starting a print. Once melted, 
the PCL was extruded out of the metal cartridge through a 22G stainless steel Luer lock 
needle tip (EnvisionTEC). The metal needle was calibrated, and scaffolds were printed at 
4.0 bar and at a speed of 1.0 mm/s. Scaffolds of various different sizes were 3D printed 
while maintaining the thickness previously mentioned. The inner pattern design of the PCL 
scaffolds was controlled by the strand orientation. For instance, the circumferentially 
aligned scaffold has the bottom layer strands aligned at 90° and the top layer strands at 
180°. Meanwhile, the radially aligned scaffold consisted of the bottom layer at 180° and 
the top layer at 90°. The diagonal orientation was achieved by printing a bottom layer at 
30° follow by the top layer at 150°. All strands were printed at a 0.4 mm distance.  
 
To perform uniaxial tensile testing, PCL scaffolds were 3D printed into dogbone 
specimens following the ASTM D1708 – 13 guidelines. The dogbone specimen was 
designed using SOLIDWORKS to have a total length of 37.5 mm, gauge length of 15 mm, 
and a width of 5.5 mm. The thickness of the PCL scaffolds ranged from 60 to 160 µm. For 
86 
uniaxial testing, a sample size of 4-7 samples were tested. To characterize the degradation 
properties of PCL scaffolds, the dogbone scaffolds were scaled down by a factor of 1.5 and 
were maintained in PBS solution at 37°C for up to 8 months. The thickness of these samples 
ranged from 30 to 50 µm. The uniaxial tensile properties of degraded samples were tested 
at 6.5 months and 8 months. A sample size of 3-6 samples was used. Degraded samples 
were compared to control samples from day 0. Before uniaxial testing, graphite markers 
were placed along the gauge length of the samples and sand paper was attached to the end 
of the dogbone specimen to enhance grip. Uniaxial testing was performed on the 
TestResources SM-500-294 with a 25 lb-f load cell at a rate of 12 mm/min and 8 mm/min 
for the dogbone with a 37.5 mm and 25 mm length, respectively. The upper and lower 
tangent moduli and the ultimate tensile strength and elongation were determined using 
MATLAB code (MathWorks), as previously described [258].  
 
The hydrophobicity of the PCL surface and its ability to crosslink with other 
biomaterials can be modulated by grafting hydrophilic poly(methacrylic acid) (PMAA) 
onto PCL via a modified two-step protocol [259]. After rinsing PCL scaffolds in ethanol 
and deionized water, samples are submerged in 30% hydrogen peroxide solution (Sigma-
Aldrich) and exposed to UV light at 37°C for 6 hours. Next, samples were rinsed with 
deionized water and placed into a 4% weight-to-volume (w/v) solution of methacrylic acid 
(MAA) in deionized water for 2 hours under UV exposure at 37°C. PCL-MAA scaffolds 
were then rinsed with deionized water for 24 hours before use. Cell compatibility and 
adhesion onto the PCL-MAA scaffolds was assessed using the alamarBlue assay and 
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immunostaining (detailed below). Using non-treated 12-well plates, iMSCs were seeded 
onto PCL-MAA scaffolds at a density of 25 x 103 cells/mL. After day 1 and day 7, samples 
were thoroughly rinsed in PBS and alamarBlue was added as 10% of the sample media 
volume and incubated at 37°C. A fluorescence excitation wavelength of 560 nm was used 
and the fluorescence emission was read at 590 nm using the BioTek Synergy 2  plate reader 
(BioTek Instruments).  The following experimental groups were utilized: PCL-MAA, PCL 
only, and controls of media only with alamarBlue were used. After the alamarBlue assay, 
samples were rinsed with PBS and then fixed in paraformaldehyde for immunostaining.  
 
Poly(ethylene glycol) diacrylate (PEGDA; ESI BIO) of molecular weight 3400 Da 
and gelatin methacrylate (GelMA; Cellink) were used to make hydrogels. A prepolymer 
solution of 5% w/v PEGDA, 10 µM Eosin Y (Santa Cruz Biotechnology), 0.375% v/v 1-
vinyl-2-pyrrolidinone (NVP; Sigma-Aldrich), and 1.5% v/v triethanolamine (TEOA; 
Sigma-Aldrich) was dissolved in PBS of 80% the total volume. The prepolymer solution 
was sterile-filtered using the Spin-X Tube Filter (Corning). Subsequently, 7.5% w/v sterile 
GelMA was added to the prepolymer solution and incubated at 37°C for 30 minutes with 
periodic vortexing prior to use. Cells were added to the solution at a concentration of 5 x 
106 cells/mL to complete the remaining 20% of the total volume. Hydrogels were made by 
sandwiching 15 µL of prepolymer solution between a hydrophobic glass slide and a cover 
slip suspended by thin silicone rubber spacers (McMaster Carr) of 0.381 mm thickness on 
each side. After assembly, the hydrogels were incubated at 4°C for 5 minutes and then 
crosslinked using a white-light source (LED Light; Braintree Scientific, Inc.) for 5 
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additional minutes. Hydrogels were removed from the glass with a spatula and placed in 
media.  
 
Rheological assessment for mechanical properties and hydrogel degradation was 
conducted on blank hydrogels and cell-laden hydrogels (5 x106 cells/mL) at the following 
time points: 1, 7, 14, 21, and 28 days. This assessment was performed on the Anton Paar 
MCR 302 stress-controlled rheometer with a 9 mm diameter, 2° measuring cone. The 
storage and loss moduli of the hydrogels were measured using dynamic oscillatory strain 
and frequency sweeps. The hydrogels were loaded on the plate, and the cone was lowered 
to the thickness of the hydrogel. An initial strain amplitude sweep was performed at ω = 
10 rad/s to determine the linear viscoelastic range of the samples. Oscillatory frequency 
sweeps between 0.5 to 30 rad/s were performed to determine the storage and loss moduli 
at 1.6% strain [260]. All samples had 5-6 technical replicates.  
 
Hydrogels were collected at day 1 and day 7 timepoints for assessment of cell 
viability. A dead control was created by collecting and incubating one hydrogel in 70% 
methanol for 30 minutes at 37°C. All hydrogels were first rinsed with PBS and stained with 
the Live/Dead™ assay, consisting of a solution of 10 µM calcein AM and 5 µM ethidium 
homodimer, for 25 minutes at 37°C. They were then collected, rinsed with PBS, and placed 
back in media. Confocal microscopy (Olympus FV100) was utilized to image the gels, and 
cell viability was quantified using an automated counter in CellProfiler. A total of 5 
biological replicates were used with a minimum of 3 technical replicates in each set.  
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3D printed PCL-MAA and GelMA/PEGDA hydrogel were combined in a 
multilayered scaffold for testing under pulsatile shear stress (PSS) conditions. For samples 
tested under PSS, PCL-MAA was cut into rectangular scaffolds of 12 x 14 mm dimension. 
Then, 8 µL of prepolymer GelMA/PEGDA hydrogel was added to the scaffold with 
silicone spacers (McMaster Carr) of 0.381 mm thickness. The spacers were used to control 
the thickness of the hydrogel. Then, a circular glass coverslip (18 mm diameter) treated 
with Rain-X® Original glass repellent (RainX) was placed on top of the hydrogel with the 
spacers on each side. Prepolymer solution contained crosslinking components as 
previously mentioned with a cell concentration of 5 x 106 cells/mL. Before crosslinking, 
samples were placed at 4°C for 5 minutes followed by white-light crosslinking for 5 
minutes at 4°C.  
 
To study the multilayered scaffold and assess the VIC phenotype and ECM production 
under the shear stress condition, a cone-in-plate bioreactor was used as previously 
described [261]. Using this system, 9 multilayered samples were loaded into the cone-in-
plate bioreactor and tested for up to 7 days under PSS with constant flow of iMSC media 
throughout the bioreactor. Control samples were multilayered scaffolds at day 0. The media 
was changed halfway through experiment. The PSS profile reached a peak shear stress of 
80 dynes/cm2 with a cycle duration of 800 ms consisting of an acceleration and deceleration 




The VIC phenotype and collagen I production was characterized in the multilayered 
scaffolds by using immunofluorescence staining and confocal microscopy (Olympus 
FV1000). For PCL scaffolds, only VIC phenotype was assessed. To stain the nucleus, 4′,6-
Diamidine-2′-phenylindole dihydrochloride (DAPI, Sigma-Aldrich) at 1 ug/mL was used 
and fluorescein-5-Maleimide at 10 µg/mL (FITC-MAL; Cayman Chemical Company) was 
used to stain the cell membrane. Hydrogels were fixed with 4% v/v paraformaldehyde for 
20 minutes, permeabilized with 0.2% Triton X-100, and incubated for 1-hour incubation 
in 1% bovine serum albumin (BSA; Sigma-Aldrich). All incubations were performed at 
room temperature thus far. Hydrogels were stained for collagen type I, aSMA, and 
vimentin using primary antibodies at 4°C overnight: mouse anti-human collagen type I 
(1:100; Abcam), mouse anti-human aSMA (1:100; Abcam), rabbit anti-human vimentin 
(1:100; Santa Cruz biotechnology). The following secondary antibodies were used: goat 
anti-mouse Alexa Fluor 647 (1:200), and goat anti-mouse Alexa Fluor 488 (1:200). Blank 
and cell-laden hydrogels were stained with secondary-only antibody as a control. The 
amount of fluorescence was quantified using CellProfiler 3.1.8, where images for each 
stain were used to quantify presence of nuclei and the VIC marker using the 
IdentifyPrimaryObjects function. Afterwards, RelateObjects and FilterObjects were used 
to determine the number of cells positive with the VIC marker of interest. The percent of 
cells positive for the VIC marker was calculated using the calculateMath function. 
Collagen type I staining was quantified using a modified similar approach, as used for VIC 
markers, the only difference being that the percent area was calculated rather than the 
percent of positive cells. A total of 3 biological samples were used, and a minimum of 6 
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images were taken from different x,y, and z locations on the PCL or the multilayered 
scaffolds.  
 
All quantitative data were expressed as the mean ± standard deviation (SD). 
Statistical analysis was performed using Prism 8 (Graphpad) and all experiments were 
tested for normality using the Shapiro-Wilk test. For uniaxial tensile testing and 
degradation experiments of PCL scaffolds, if samples were normally distributed, an 
unpaired ordinary one-way ANOVA with Holm-Sidak’s multiple comparisons test was 
used, while for samples not normally distributed, a Kruskal-Wallis ANOVA test with 
Dunn’s multiple comparison test was performed. As for cell compatibility and cell 
viability, an unpaired t-test and paired t-test were used to compare between day 1 and day 
7, respectively. To quantify the percent of cells with positive  aSMA and vimentin 
expression an ordinary one-way ANOVA and a Tukey’s multiple comparison test was 
used. For the shear stress studies, an unpaired t-test was used for comparing the cells 
positive for aSMA and vimentin expression, as well as for the percent area covered by 
collagen type I. For all experiments, unless otherwise stated, sample size n = 3-5 and 








The mechanical properties of PCL scaffolds of three strand orientations 
(circumferential, radial, and diagonal) were evaluated, as shown in Figure 17a. The 
Cauchy-Green stress-strain curve demonstrates a similar shape among the different strand 
orientations, where there is an initial phase up to 7-12% Green strain, followed by a plastic 
deformation phase thereafter. In Figure 17b, the upper tangent modulus (UTM) and lower 
tangent modulus (LTM) were calculated for all three strand orientations. The average UTM 
was 5.2 MPa for circumferential strand alignment, 3.7 MPa for radial strand alignment, 
and 4.1 MPa for the diagonal strand alignment on PCL scaffolds. The circumferential 
scaffolds were statistically significant when compared to the radially aligned scaffolds, and 
no significance was determined when compared to diagonal scaffolds. As for the LTM, no 
statistical significance was determined among all three alignments, and the average LTM 
was 139.8, 204.2, and 137.6 MPa for the circumferential, radial, and diagonal scaffolds, 
respectively. Furthermore, the ultimate tensile strength, which describes the materials 
capacity to withstand the loads with a tendency to elongate the scaffold, was the highest 
for the radially aligned scaffolds at 168.1 MPa, while the circumferential UTS was 155.2 
MPa followed by 92.8 MPa for the diagonal scaffolds. There was no statistical difference 
between the UTS of circumferential and radial scaffolds; however, the diagonal scaffold 
was statistically lower when compared to the radial scaffolds. Lastly, the UTE for the radial 
scaffolds was significantly higher than the other two strand orientations with a strain of 




Figure 17. Mechanical properties of PCL scaffolds of three different strand orientations.  
A) Representative images of the strand orientation of 3D printed PCL scaffolds used for 
tensile testing. The direction in which samples were subjected to tensile testing is 
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demonstrated on the right. B) Cauchy-green stress-strain curve for the circumferential, 
radial, and diagonal scaffolds, where the moduli for PCL scaffolds was calculated from 
two different regions, the upper and the lower tangent modulus (UTM and LTM). C) The 
mechanical properties of the PCL scaffolds were characterized by four properties: the 
UTM, LTM, ultimate tensile strength (UTS), and ultimate tensile elongation (UTE). N = 
4. *p<0.05; ** p<0.01; ***p<0.001. Scale bar = 5 mm. 
 
The mechanical properties of PCL scaffolds of circumferential strand orientation 
were assessed to determine changes in bulk properties due to degradation (Figure 18). 
Circumferential PCL scaffolds did not show evidence of degradation based on their UTM 
and LTM properties; however, there was a significant decrease in UTS and UTE when 
comparing 0 to 8 months. The UTS significantly decreased from 155.2 MPa to 62 MPa 
after 8 months, while the UTE also significantly decreased from 19.7 MPa to 8.9 MPa. 
Additionally, a decrease in sample thickness was observed after 8 months of degradation 
as shown in Supplementary Figure 37.  
 
Figure 18. Characterization of degradation of PCL scaffolds of circumferential strand 
orientation. The UTM, LTM, UTS, and UTE were characterized from uniaxial tensile 
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and at 6.5 and 8 months the mechanical properties were characterized and compared to 
month 0 scaffolds. N = 3-7. One-way ANOVA comparing 0 to 8 months. * p<0.05; ** 
p<0.01.  
 
The cellular health and metabolic function of iMSCs seeded on either PCL-MAA 
or PCL scaffolds were assessed at day 1 and day 7 as shown in Figure 19. Using 
alamarBlue, the level of fluorescence was normalized to day 1 and then compared between 
the two samples. PCL scaffolds treated with methacrylic acid (PCL-MAA) were 
statistically higher than PCL scaffolds, where there was 4 times more fluorescence.  
Figure 19. iMSC metabolism when seeded on PCL scaffolds. PCL-MAA and PCL were 
seeded with iMSCs and alamarBlue reagent was used to assess the cellular health and 
metabolic function of adhered cells. The level of fluorescence was normalized to day 1 and 






























Cell metabolism using the AlamarBlue Assay
96 
 
In addition to assessing whether or not cells adhered onto the PCL scaffold, the 
effects of the scaffold on the iMSC phenotype was important to characterize. Scaffolds 
were stained for  aSMA and vimentin and the number of positive cells with aSMA and 
vimentin expression were quantified. On average, 30% of the iMSCs seeded on PCL 
stained positively for  aSMA, regardless of surface treatment of MAA. Meanwhile, 70% 
and 50% of cells stained for vimentin when seeded on PCL-MAA and PCL, respectively. 
While, 30% of the cells seeded on tissue culture (TC) expressed vimentin. In Figure 20c, 
iMSCs seeded on PCL-MAA scaffolds have positive diffuse staining of vimentin in most 
of the cells, with a few cells staining for  aSMA stress fibers. Cells seeded on the PCL only 
scaffold also have diffuse staining of vimentin, except cells do not demonstrate distinct 
stress fibers of aSMA and rather have aSMA staining at the focal adhesion sites. On the 
TC plate, iMSCs have minimal staining of vimentin and staining of very distinct stress 
fibers of aSMA.  
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Figure 20. Quantification of  aSMA and vimentin expression of iMSCS seeded on PCL-
MAA, PCL, and tissue culture plate (TC). A,B) Percentage of cells that stained positive for 
 aSMA and vimentin was determined from immunostaining images using CellProfiler 
software. A total of 3 biological samples were used, and a minimum of 6 images were taken 
from different x, y, and z locations on the PCL. C) Immunostaining images of iMSCs 
seeded on PCL-MAA, PCL, and TC. N = 3. One-way ANOVA comparing all experimental 
groups. *p <0.05. DAPI – blue, vimentin – green, and  aSMA – red. Scale bar 50 µm.  
 
For the spongiosa/ventricularis layer of the valve scaffold, hydrogels of GelMA 
and PEGDA were used. The mechanical properties of cell-laden hydrogels are important 
























































Mechanical properties were also used as a measure of degradation over the course of 28 
days. The storage and loss moduli of blank and cell-laden hydrogels were measured over a 
range of frequencies, as shown in Supplemental Figure 38, and measurements taken at 1.6 
Hz were compared across groups, as shown in Figure 21. The storage moduli of blank and 
cell-laden hydrogels indicated a significant difference, with cell-laden hydrogels exhibiting 
a lower storage modulus on average compared to that of blank hydrogels. However, 
comparisons of storage moduli across 28 days showed no significant changes over the 
experimental time period in either group. Similarly, a significant decrease in loss modulus 
was also observed between blank and cell-laden hydrogels. In loss moduli, significant 
differences over time were observed between hydrogels, specifically between day 7 and 
day 28 of blank hydrogels. These results indicate that while variations in storage and loss 
moduli exist between groups, cell-laden hydrogels are not degrading within the course of 
28 days.  
Figure 21. Rheological characterization. Storage moduli (a) and loss moduli (b) of blank 
GelMA/PEGDA hydrogels and cell-laden GelMA/PEGDA hydrogels over 28 days 
measured by rheology. N = 5 - 6. Two-way ANOVA comparing Blank vs. Cells. ** p < 
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Evaluating cell viability within these hydrogels is important to ensure that they are 
able to produce ECM components to remodel and regenerate the leaflet. As shown in 
Figure 22, iMSCs encapsulated in 7.5% w/v GelMA and 5% w/v PEGDA hydrogels 
remained viable at 92% by day 1. By day 7, iMSC viability decreased to 80%. While the 
decrease from day 1 to day 7 was significant, iMSCs still remained viable encapsulated 







Figure 22. Assessment of cell viability using Live/Dead assay. A) Cell viability of iMSCs 
encapsulated in GelMA/PEGDA hydrogels at day 1 and day 7. Cell viability decreased 
from 92% to 80% over 7 days. B) However, cells still remained viable within the hydrogels 
up to 7 days. N = 5. Paired t-test, *** p < 0.001. Green – Calcein AM. Scale bar 50 µm.  
 
To create a multilayered leaflet, the PCL and GelMA/PEGDA components were 
crosslinked together. Samples were loaded into the cone-in-plate bioreactor for assessing 
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cell-laden scaffolds.  In Figure 23a, the expression of  aSMA and vimentin was quantified 
and compared between day 0 and day 7 PSS. In the multilayered scaffolds, 18% of the 
encapsulated cells were positive for  aSMA at day 0. After day 7 of PSS, this number 
increased to an average of 23% of the cells positively expressing  aSMA. When staining 
for vimentin, 16% and 28% of the cells expressed vimentin in the multilayered scaffolds 
at day 0 and at day 7 PSS, respectively. There was no statistical difference between the day 
0 and day 7 PSS for both  aSMA and vimentin expression. Representative images of the 
immunostaining of aSMA and vimentin are demonstrated in Figure 23b. At day 0, there is 
diffuse staining of aSMA present and then cells have a combination of diffuse and punctate 
staining of aSMA and punctate staining of vimentin after 7 days of PSS conditions. No 
evidence of background staining is present in the secondary antibody only images for 
 aSMA and vimentin (data not shown).  
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Figure 23. Quantification of  aSMA and vimentin expression in cell-laden multilayered 
scaffolds. A)  aSMA and vimentin expression was quantified by determining the number 
of positive cells with aSMA and vimentin expression at D0 and post-D7 in PSS conditions. 
A total of 3 biological samples were used, and a minimum of 6 images were taken from 





















































immunostaining of  aSMA and vimentin at D0 and D7 PSS. N = 3. Unpaired t-test – no 
significance. DAPI – blue,  aSMA – Red, and vimentin – Green. Scale bar 25 µm. 
Collagen type I deposits were also quantified through immunostaining and 
compared between day 0 and day 7 PSS in Figure 24a. At day 0 there was minimal evidence 
of collagen type I and by day 7 PSS 0.34% of the imaged area was stained positively for 
collagen type I. This increase in collagen type I was determined to be statistically higher 
when compared to day 0. In Figure 24b, immunostaining demonstrates minimal to no 
staining of collagen type I, at day 0 and at day 7 PSS, we observe diffuse collagen type I 
staining surrounding the cell membrane (stained in green). In control samples stained only 
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Figure 24. Quantification of collagen type I deposits in cell-laden multilayered scaffolds. 
A) Collagen type I was quantified by determining the percent area of collagen type I 
staining over the area of total image. A total of 3 biological samples were used, and a 
minimum of 6 images were taken from different x, y, and z locations on the multilayered 
scaffold.  B) Confocal images of immunostaining of Collagen type I at D0 and D7 PSS. N 
= 3. Unpaired t-test. p<0.0001. DAPI – blue, Collagen type I – Red, and cell membrane 
(FITC-MAL) – Green. Scale bar 25 µm. 
 
Heart valve tissue engineering has the potential to address the limitations of current 
mechanical and bioprosthetic heart valve implants. Most importantly, TEHVs could 
tremendously impact the pediatric population, who currently rely on heart valve implants 
that were designed and made for adults. In this aim, our goal was to develop a multilayered 
valve leaflet using PCL and a hydrogel-based bioink to generate a mechanically functional 
aortic TEHV that has the ability to promote healthy VIC-like phenotype and ECM 
production, and is capable of degrading over time. To engineer a functional aortic TEHVs, 
a rationally-designed heart valve leaflet composed of both synthetic and natural polymers 
was developed.   
The heart valve leaflet was designed considering the structural and mechanical 
properties of the fibrosa layer in native leaflets, where the collagen fibers are 
circumferentially aligned, and the mechanical properties are anisotropic [263]. In this aim, 
PCL was 3D printed in three different strand orientations to determine which scaffold 
would yield mechanical properties similar to native leaflets. The stress-strain curve of the 
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PCL scaffolds was observed to have two phases with distinct tangent moduli and the shape 
of the curve suggests the scaffold is not relatively elastic. The UTM of the PCL scaffolds 
were within the physiological range of 4 – 13 kPa [122], and the circumferential UTM was 
statistically higher compared to the radial. This suggests that strand orientation can produce 
anisotropy because at different orientations, a significant difference in the UTM is 
observed. At the UTM, it is important to notice the PCL scaffolds undergo plastic 
deformation. The LTM, regardless of the strand orientation, was much higher than native 
tissue, where there was no statistical difference among the different strand orientations. 
Given that native leaflets have a modulus of 4 – 13 kPa [122], it suggests that under 
physiological conditions it is unlikely that the PCL scaffolds will undergo any major 
deformation or fracture.  
A reason why the PCL scaffolds have two different tangent moduli could be due to 
the manufacturing process used. PCL scaffolds were 3D printed using strands of melted 
polymer which created “crosslinking” between strands, yielding a very high initial tangent 
modulus. This can describe why we observe a stiffer material reinforced by the crosslinking 
of the strands, regardless of strand orientation. Once the crosslinks have unlinked, then we 
observe the true modulus, where the PCL scaffold is more compliant. The statistical 
difference between all three strand orientations for the UTE indicates that the introduction 
of different orientations can affect the overall UTE of the scaffold, which suggests that 
strand orientation can introduce anisotropic properties to the scaffolds. Overall, PCL 
scaffolds have some resemblance to the native leaflet. For further studies, only 
circumferentially aligned PCL scaffolds were investigated, as these strands most closely 
resemble collagen fiber alignment. Given that we are engineering a TEHV that has the 
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capacity to degrade and remodel over time, it was important to assess short-term 
degradation to ensure that this material would not degrade quickly.	Degradation of the PCL 
scaffolds is characterized to be slow and not evident in the UTM and LTM properties of 
the circumferential PCL scaffolds after 8 months. However, there was evidence of some 
degradation through the significant decrease in UTS and UTE. Some evidence of 
degradation is to be expected as PCL has slow degradation of  24-36-months [264]. 
Next, the PCL scaffold was surface-treated with poyl(methacrylate acid) in order to 
reduce hydrophobicity and to ensure that this material can be crosslinked with the hydrogel 
biomaterial. The health of iMSC metabolism post-surface treatment was important to 
assess to ensure cells interacting with the PCL remained viable and healthy. AlamarBlue 
data demonstrated that iMSCs have higher metabolic activity compared to PCL-only 
scaffolds, suggesting that decreasing hydrophobicity led to more cellular metabolic 
activity. It could also suggest that more cells were able to adhere onto the PCL-MAA 
scaffold compared to PCL scaffolds. Previous studies have demonstrated that when 
hydrophobicity is decreased, more cell adhesions are observed [265]. Furthermore, it was 
important to characterize the VIC-like phenotype of iMSCs seeded on PCL-MAA scaffolds 
given the stiffness of PCL and its potential to elicit an activated myofibroblast-like 
phenotype. On average, 35-40% iMSCs adhered on PCL scaffolds were positive for 
 aSMA expression, regardless of MAA treatment. Interestingly, iMSCs were 50-60% 
positive for vimentin expression, suggesting that iMSCs, when seeded on PCL, are more 
VIC-like cells. If iMSCs remain activated through long-term expression of  aSMA, an 
alternative is to utilize ascorbic acid to modulate the cell phenotype while promoting ECM 
remodeling [211]. 
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The next component of the multilayered leaflet is the hydrogel-based bioink 
composed of GelMA/PEGDA. The degradation of this material is important to characterize 
as this material should ideally degrade slowly to enable cells to remodel and produce ECM. 
Overall, there was significant difference in the storage and loss modulus between blank 
and cell-laden hydrogels. A lower modulus for cell-laden hydrogels could be caused by a 
high seeding density, which can reduce the number of crosslinking sites available. In a 
previous study,  when cells were introduced into a quasilaminate scaffold, composed of 
varying stiffness of PEGDA,  a similar decrease in modulus was observed [131]. However, 
no difference was observed over different time points suggesting low to minimal 
degradation of the GelMA/PEGDA hydrogels short-term. If necessary, slow MMP-
cleavable degradation peptides may need to be introduced into the GelMA/PEGDA bioink 
to control degradation [266]. The cell viability of iMSCs was assessed in cell-laden 
hydrogels of GelMA/PEGDA, and while there was a decrease in cell viability, 80% 
viability was considered acceptable for future experiments. Thus, suggesting that overall, 
the GelMA/PEGDA hydrogel is suitable for use in the valve leaflet.  
The VIC-like phenotype and collagen type I production was studied in the 
multilayered scaffolds under pulsatile shear stress conditions for 7 days. To assess whether 
there were any changes to the phenotype of iMSC and whether iMSCs were capable of 
producing collagen type I, scaffolds were immunostained for  aSMA, vimentin, and 
collagen type I. We have previously shown that iMSCs in PEGDA hydrogels transition 
from an activated VIC-like phenotype to a more quiescent state, and that these cells have 
the capacity to produce collagen type I shortly after 7 days under static conditions [11]. 
Under PSS, we did not observe any changes in aSMA and vimentin expression, where 
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there were 20% positive cells for aSMA and vimentin.  The lack of significance could be 
explained by biological variation and a small sample size. Results from immunostaining 
suggests that under PSS and in the multilayered scaffold, we do not observe an activated 
VIC-like phenotype nor expression of vimentin. It is worthwhile noticing that this is only 
day 7 and that a longer time point may be necessary. While no changes in cell phenotype 
were observed, the amount of collagen type I produced was significantly higher at day 7 
under PSS compared to day 0. Furthermore, the diffuse staining appears to be surrounding 
the cells suggesting that collagen type I production is possible under PSS and in the cell-
laden multilayered leaflet scaffold. While the percent of collagen of the overall area imaged 
is low (0.34%), it is important to recognize the amount of collagen produced is influenced 
by the number of cells present. A limitation for assessing collagen I is the small amounts 
of cells visualized during imaging, and thus a possible reason for the 0.34% of the area 
positively stained for collagen I. In future studies, collagen type I content can be measured 
by hydroxyproline assay; however, the amount of hydrogel collected will need to be 
increased to be able to detect collagen using this assay. Another component to consider for 
future studies is increasing the duration of this experiment, because through previous 
studies we have demonstrated that cells produce large amounts of collagen at day 28 [11]. 
This may be a challenge with the cone-in-plate bioreactor as it is not built for time points 
longer than 7 days. An alternative to evaluate the production of collagen is to use a heart 
valve bioreactor, where longer time points can be sustained.  
 
In this aim, we demonstrated a multilayered heart valve leaflet can be composed of 
3D printed PCL and a hydrogel layer to recapitulate structural features of native leaflets. 
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Each material used for the multilayered leaflet was assessed for its mechanical properties 
and its interactions with iMSCs to ensure that cells remained viable and maintained a 
healthy VIC-like phenotype. Furthermore, the multilayered leaflet under pulsatile shear 
stress conditions resulted in collagen type I production suggesting the leaflet is capable of 
ECM production over time. While our results are promising, future studies are necessary 
to evaluate the multilayered leaflet under aortic valve conditions as well as assess its 









CHAPTER 6  PCL TEHVS FUNCTION UNDER 
PHYSIOLOGICAL AORTIC VALVE FLOW CONDITIONS 
 
Most TEHVs have been developed for the pulmonary position as TEHVs capable of 
withstanding aortic valve conditions are required to be more durable. In this aim, a 3D 
printed PCL leaflet of circumferential strand orientation was assembled onto a valve stent 
to evaluate whether this layer of the TEHV leaflet, which is designed to be the load-bearing 
layer, can withstand aortic valve flow and pressure conditions. Using a left-ventricle flow 
loop, the hemodynamic profile of the PCL-TEHVs was tested under aortic heart valve 
conditions and the following parameters were computed: the effective orifice area, mean 
and max transvalvular pressure gradient, regurgitation volume, and leakage volume. 
Hemodynamics studies of the PCL-TEHV resulted in similar EOA and mean transvalvular 
pressure gradient to commercially available valves. In addition, there was no evidence of 
leakage or regurgitation suggesting the PCL-TEHV properly functions under aortic valve 
conditions. While the PCL-TEHV is promising, future studies are necessary to evaluate the 
multilayered leaflet under aortic valve conditions, fatigue properties, and overall 






Thus far in the TEHV field, numerous valve constructs have been created from 
decellularized tissue, molding, electrospinning, and 3D bioprinting [10, 41, 267]. Several 
of these conduits have been tested for feasibility in preclinical animal models [147, 268, 
269]. Universally, these TEHVs lost their functionality due to leaflet retraction and 
valvular incompetence caused by maladaptive cellular remodeling - often observed after 
8-12 week in vivo [39, 117, 223, 270-272]. This issue has only been recently investigated 
by a study conducted by Emmert et al., where computational modeling was used to better 
design heart valves using data on cellular remodeling due to mechanical forces, valve 
leaflet geometry, and hemodynamic conditioning of valves [273]. In Emmert et al.’s study, 
a functional and biological competent pulmonary valve conduit was placed in a relevant 
sheep model for over 1 year [273]. While the results from Emmert et al. study are exciting, 
a cell-laden aortic TEHV with long-term functionality has yet to be developed and tested 
in physiological flow conditions for long-term use. Thus, there is a need to develop a 
multilayered 3D scaffold with the microstructure of each leaflet layer for improved 
mechanics, and cellular integration for remodeling potential.    
3D printing enables every component of the TEHV to be customized and easily 
adapted to a patient. CAD modeling from CT scans can be easily implemented to generate 
a 3D model of the patient's aorta. With those dimensions, a valve ring can be 3D printed 
using biodegradable materials and subsequently the leaflet can be mounted onto the valve 
ring. Combined, the valve ring and valve leaflets will be biodegradable and designed to 
facilitate biological integration with the host during its slow degradation process. In 
addition to designing the valve ring, we have also developed a rapid assembly method to 
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mount valve leaflets onto the valve ring. This method involves a single scaffold for the 
valve leaflet which is then fixed to the aortic valve ring using either sutures or 
cyanoacrylate. The use of 3D printing and our assembly method enables aortic heart valves 
to be manufactured as fast as six hours.  
Our approach takes advantage of 3D bioprinting to replicate the collagen alignment 
in the fibrosa layer. The use of different biomaterials allows us to develop a functional 
valve that promotes controlled remodeling to minimize leaflet retraction. As observed 
previously by Emmerts et al. work, the design of the leaflet as well as the properties of the 
material are crucial for proper cellular remodeling. The scaffolds we will test strategically 
utilize 3D printed strands that capture the anisotropic properties at the micro-level, and as 
for the macro-geometry we are able to rapidly test different leaflet geometries to quickly 
identify an ideal environment for cellular remodeling. This detail-oriented engineering 
approach will create a new pathway for patient-specific valves to be developed.  
For clinical translation of our TEHV, the multilayered scaffold will need to be 
assessed under physiological flow conditions before in vivo studies. This is a critical step 
in determining the hemodynamic profile of the TEHV as well as the capacity for it to 
undergo ECM remodeling. At this point, most TEHVs are tested under pulmonary flow 
conditions as the flow profile is similar to the aortic valve, but at a lower magnitude [133]. 
Under pulsatile flow conditions, TEHVs are assessed for potential clinical stenosis or 
regurgitation and for the level of ECM deposition. While the pulmonary flow conditions 
are similar, our goal is to develop an aortic valve. Thus, we will utilize a pulsatile flow 
loop mimicking the aortic valve position. We hypothesize that when our multilayered 
scaffold is assembled onto a valve ring and tested under aortic valve conditions, the TEHV 
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will have similar hemodynamic profile to clinically available valve protheses and have the 
capacity to induce ECM remodeling by the encapsulated valve cells. To test this 
hypothesis, we will 3D print the valve ring, assemble the multilayered leaflet to the ring, 
and test the valve under pulsatile aortic valve conditions.  
 
 
To build a heart valve prototype, the two components necessary are the valve stent 
and the valve leaflet. Using SOLIDWORKS, a valve stent of 17 mm inner diameter and 19 
mm outer diameter was designed referencing Thubrikar’s work [274]. The valve stent was 
3D printed using the Stratasys Objet30 Pro and the following two materials, the Objet 
RGD875 (VeroBlackPlus; Stratasys) and the FullCure 705 (Support Resin; Stratasys). A 
single valve leaflet composed of PCL-MAA scaffold was attached to the valve stent via 
cyanoacrylate (Loctite® 404) ensuring that 2 mm of excess PCL remained above the valve 
stent posts.  
 
To determine the hemodynamics of the heart valve prototype, TEHVs were placed in 
a left-heart flow loop, previously detailed [275]. The simulator consists of four main 
components: flow, pressure, data acquisition, and flow visualization. Pressure and flow 
data at 1000 Hz over 100 simulated cardiac cycles with 3 technical repeats. Two cardiac 
outputs, 2.5 and 5 L/min, were evaluated using a water-glycerin mixture (36% glycerin), 
which recapitulates the kinematic viscosity of blood. Using previous methods [275, 276], 
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the following parameters were computed: the effective orifice area, mean and max 
transvalvular pressure gradient, regurgitation volume, leakage volume. The time to open 
and close for the valve during one cardiac cycle was also determined through a slow-
motion video at 240 frames per second using an iPhone Xs. A total of 4 valves were tested 
under aortic valve flow and pressure conditions.  
 
All quantitative data were expressed as the mean ± standard deviation (SD). 
Statistical analysis was performed using Prism 8 (Graphpad) and all experiments were 
tested for normality using the Shapiro-Wilk test.  For statistical analysis of hemodynamic 
data, a one-way ANOVA with post hoc Tukey-Kamer test was used to compare the 
hemodynamic measurements (mean/max TVPG, EOA, leakage volume, etc.) between the 
TEHVs. For all experiments, unless otherwise stated, sample size n = 4 or greater and 




To demonstrate feasibility of using PCL as the load-bearing layer of the 
multilayered leaflet scaffold, a valve stent composed of three posts was first designed to 
have an inner diameter of 17 mm and a 19 mm outer diameter as shown in Figure 25a. In 
order to test in the flow loop, an additional outer ring (Figure 25b) was added to the valve 
stent for proper placement. The PCL leaflet was 3D printed with circumferential strand 
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orientation as shown in Figure 25c. Next, the leaflet was successfully wrapped around the 
valve stent using cyanoacrylate. The placement of the leaflet was measured to have an 
excess length of 2 mm above the valve post. In Figure 25 (d,e) the mounted PCL leaflet 
can be observed in an open and closed state. This approach enabled consistency between 
valve prototypes and an average of 30-40 minutes assembling time.  
 
 
Figure 25. TEHV prototype components. A) Valve stent of 17 mm ID and 19 OD was 
designed using SolidWorks. B) An additional outer diameter at the bottom of the valve 
stent was added to enable placement and fixation to the pulsatile flow loop. C) Image of 
the PCL valve leaflet with circumferential strand orientation. D, E) Completely assembled 







The hemodynamic profile of the TEHV was characterized using a pulsatile flow 
loop capable of mimicking physiological flow rates. First, the opening and closing of the 
valve was observed using slow-motion video. The TEHV experienced rapid valve opening 
at less than 0.1 seconds followed by 0.2 seconds of ejection time. Rapid valve closing 
occurred at 0.4 seconds. These three phases were continuously observed throughout the 
100 cardiac cycles. A side-view and cross-sectional view of the valve opening, and closing 
can be observed in Figure 26. Valves were inspected after hemodynamic testing and no 
visible deformation or damage was observed. Next, the hemodynamic profile of the 
TEHVs was characterized through four parameters: effective orifice area (EOA), changes 
in volume, mean transvalvular pressure gradient (TVPG), and maximum transvalvular 
pressure gradient (max. TVPG). In Figure 27, the EOA at 2.5 L/min cardiac output was 1.2 
cm2, and at 5L/min the EOA was 1.4 cm2. At 5L/min cardiac output, the TEHV was within 
the EOA range for the St. Jude mechanical valve and MitroFlow valve, which were 1.5 and 
1.2 cm2, respectively [277, 278]. As for the changes in volume, minimal regurgitation was 
detected for both cardiac outputs. The closing volume of the valve was 3.2 and 3.4 mL for 
the 2.5 L/min and 5L/min. Leakage volume was minimal for both cardiac volumes, with 
the maximum volume reaching 2.8 mL. Another metric utilized to assess the hemodynamic 
profile of the TEHV is the mean TVPG, which was 10.4 mm Hg at a 5L/min cardiac output, 
and this was even lower at 2.9 mm Hg for the 2.5L/min cardiac output. Again, the TEHV 
has comparable mean TVPG to the St. Jude and Mitroflow valves, which were reported to 
be 10.9 to 11.4 mm Hg, respectively [277, 278]. The max TVPG at 2.5L/min was 23.5 mm 
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Hg and at 5L/min cardiac output, the max TVPG peaked at 37 mm Hg. These values are 
higher than the commercially valves, which had average max TVPG of 20.2 mm Hg.   
 
Figure 26. TEHV opening and closure during a cardiac cycle.  A TEHV of 19 mm OD and 
17 mm ID with a 40-um thick leaflet scaffold was tested under aortic valve condition of 70 
beats per minute with 5L/min output for 100 cycles. Through the transparent polycarbonate 
test chamber, a slow-motion video of 240 frames per second was captured. The TEHV 
opened and closed at 0.4 seconds. 
0 s  0.3 s 0.4 s 0.1 s 
117 
	
Figure 27. Evaluation of valve performance under pulsatile flow conditions. Effective 
orifice area of the TEHV was 1.5 cm2 at 2.5 and 5 L/min and demonstrated comparable 
EOA to St. Jude Reagent valve and MitroFlow valve [279]. The mean transvalvular 
pressure gradient (TVPG) of the PCL valve also had comparable values to commercially 
available valves. At both the cardiac outputs of 2.5 and 5 L/min, there was minimal 
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While developing a multilayered leaflet capable of repairing and remodeling is 
important, it is just as essential to test whether this leaflet is capable of withstanding aortic 
valve flow and pressure conditions. In aim 3, the feasibility of using the PCL as the fibrosa 
layer of the manufactured heart valve leaflet described in CHAPTER 5  is evaluated under 
physiological aortic flow and pressure conditions.  
Previous groups have developed TEHVs that function under pulmonic valve 
conditions [39, 147, 280]; however, to this date only one TEHV has been capable of 
withstanding aortic conditions, which is an off-the-shelf decellularized TEHV [270]. Thus, 
the objective was to evaluate whether our rational-design for the multilayered leaflet has 
the capacity to mechanically function under aortic physiological flow conditions. In this 
aim, only the PCL layer was tested under flow conditions. Future studies will include the 
multilayered leaflet with the cell-laden hydrogel layer. Before testing, the PCL scaffold 
was assembled onto a valve stent with reproducibility. The TEHVs tested under aortic 
valve conditions demonstrated EOAs comparable to the St. Jude mechanical valve and 
MitroFlow valve of similar size under 5L/min cardiac output [277, 278]. Furthermore, there 
were minimal changes to the regurgitation, closing, and leakage volumes suggesting the 
TEHVs were opening and closing properly. The mean transvalvular pressure gradient was 
also similar to the St. Jude mechanical valve and MitroFlow valves. The only difference 
was the maximum transvalvular pressure gradient, which was much higher than 
commercially available valves. This could be due to a number of factors such as obstruction 
during hemodynamic testing, the valve stent material, as well as the valve leaflet itself. The 
underlying reason for a max transvalvular pressure gradient will be further investigated by 
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conducting PIV hemodynamic studies. Interestingly, this higher max TVPG could be due 
to the properties of a polymer leaflet. In a previous study, a polymeric valves composed of 
a combination styrene block copolymers with a 21 mm inner diameter exhibited a max 
TVPG of 30 and 43 mm Hg when testing two different blends of the block polymers [281]. 
This could suggest heart valve composed of polymers have a different hemodynamic 
profile compared to biological or mechanical valves.  
Thus, it would be valuable to have a control valve to compare to the TEHV developed 
in this study. Perhaps, it may not be reasonable to compare our TEHV to a mechanical 
valve such as the St. Jude because these valves are very different in their design and 
materials. Alternatively, a control could be a valve composed of the same valve stent with 
a pericardium leaflet, or alternatively a similar commercially available valve, which can be 
either a biological heart valve such as the MitroFlow valve or a polymeric heart valve such 
as Poli-valve [281].  
While these are initial tests, the TEHV composed of just the PCL layer demonstrates 
promising results and future studies will involve the multilayered leaflet. Once the 
feasibility of the multilayered leaflet is assessed under hemodynamic conditions, the next 
step is to evaluate the performance of this valve long-term in a bioreactor and eventually 
in an in vivo model at the pulmonary and aortic position.  
 
Most TEHVs have been developed for the pulmonary position as TEHVs capable of 
withstanding aortic valve conditions are required to be more durable. In this aim, the PCL 
component of the multilayered leaflet was assembled into a valve stent to evaluate whether 
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this layer of the TEHV, which is designed to be the load-bearing layer, can withstand aortic 
valve flow and pressure conditions. The hemodynamic studies demonstrate the TEHV has 
similar EOA and mean transvalvular pressure gradient to commercially available valves. 
While TEHV is promising, future studies are necessary to evaluate the multilayered leaflet 





CHAPTER 7  CONCLUSION AND FUTURE DIRECTIONS 
Heart valve disease is an increasing clinical burden associated with high morbidity and 
mortality [14-16]. Congenital heart defects contribute to the prevalence of heart valve 
disease and account for 1 to 2% of births [227]. Meanwhile, rheumatic fever is the main 
cause for heart valve disease in developing countries [8, 9]. With limited biological 
diagnostics or drugs to prevent heart valve disease, pediatric patients can have the 
following interventions: valve repair, replacement, or the Ross procedure. Most patients 
are treated with a mechanical or a biological valve replacement when valve repair or 
surgical interventions fail. While prosthetic valves can last up to 10 years, there is risk of 
calcification, thrombogenicity, and leaflet tearing [10]. For pediatric patients, 
commercially available implants are limited by size and most importantly they fail to grow. 
Without the regenerative capacity, children may require several surgical interventions, 
which introduces another level of risk for thromboembolism and operative mortality [31, 
282]. An ideal heart valve for children would be available in various sizes, non-
immunogenic, exhibit durable hemodynamics, and have the potential to couple with 
somatic growth. To address and minimize the numerous risks with current heart valves, 
this study aimed to develop tissue engineered heart valves (TEHVs) by combining three 
components, 1) autologous cells, 2) regenerative biomaterials, and 3) 3D bioprinting to 
generate a heart valve scaffold capable of promoting and enabling mechanical function in 
the aortic valve position, growth, and biological integration.    
This thesis project is a first step toward replacement valve therapy for children, where 
technology and stem cell advancements have been applied to generating a tissue engineered 
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heart valve.  In Aim 1, developing a suitable cell source for tissue engineering is a critical 
component for the success and durability of TEHVs. In this aim, we addressed this problem 
by differentiating iMSCs from iPSCs and then further maturing these cells into VIC-like 
cells by introducing them into a 3D culture designed to mimic the properties of the valve 
leaflets. First, a modified differentiation protocol was utilized to differentiate iPSCs into 
iMSCs using a feeder-free approach. Next, iMSCs were encapsulated into PEGDA 
hydrogels to study the effects of a 3D culture in the maturation of iMSCs into VIC-like 
cells. Encapsulated iMSCs demonstrated a transition from an activated VIC-like phenotype 
to a more quiescent state. In addition, collagen deposition was identified in cell-laden 
PEGDA hydrogels, corresponding to the potential use of iMSCs as a cell source for 
TEHVs. As such, these experiments highlight the importance of a 3D culture environment 
to influence cell phenotype and function as well as contribute a potential new option for 
seeding TEHVs. As for future studies, iMSCs would need to be studied long-term to 
understand their regenerative and remodeling potential, such as the production of 
proteoglycans, elastin, and matrix metalloproteinases. The use of PEGDA is to 
demonstrate, that as a simplified model, iMSCs can progress towards a VIC-like 
phenotype. However, further work is necessary to study these cells, long-term, as a 
potential cell source for heart valve tissue engineering, especially in more physiologically 
relevant conditions.   
In Aim 2, we demonstrated a multilayered heart valve leaflet composed of 3D printed 
PCL and a hydrogel layer can recapitulate structural features of the native leaflets. Both 
materials had physiologically relevant mechanical properties, slow degradation, and   
maintained a healthy VIC-like phenotype. Furthermore, the multilayered leaflet under 
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pulsatile shear stress conditions resulted in collagen type I production suggesting the leaflet 
is capable of ECM production over time. While our results are promising, future studies 
are necessary to evaluate the long-term remodeling of multilayered leaflet through the cell-
laden iMSCs. It is important to study whether there is evidence of leaflet retraction over 
the remodeling phase, as this has commonly been an issue with other TEHVs [254]. In 
addition, future studies will need to investigate the addition of VECs to the outer surfaces 
of the scaffold as VECs are responsible for rendering the leaflet non-thrombogenic. As 
mentioned before, nitric oxide (NO) production of VECs is considered to be protective and 
maintains VICs in a quiescent phenotype [92]. Apart from this, VECs also regulate the 
immune and inflammatory responses by preventing coagulation through release of tissue 
factor and thrombin inhibitors, and preventing platelet activation by releasing nitric oxide, 
prostacyclin, and exonucleotidases [283]. 
In Aim 3,  the objective was to evaluate the feasibility of using the PCL as the fibrosa 
layer of the manufactured heart valve leaflet, described in CHAPTER 5 , under 
physiological aortic flow and pressure conditions. Most TEHVs have been developed for 
the pulmonary position as TEHVs capable of withstanding aortic valve conditions need to 
be more durable. In this aim, the PCL component of the multilayered leaflet was assembled 
onto a valve stent to evaluate whether this layer of the TEHV, which is designed to be the 
load-bearing layer, can withstand aortic valve flow and pressure conditions. The 
hemodynamic studies demonstrate the TEHV has similar EOA and mean transvalvular 
pressure gradient to commercially available valves. While these findings are promising, 
future studies are necessary to evaluate the multilayered leaflet, which includes the 
GelMA/PEGDA hydrogel layer, under aortic valve conditions. The TEHVs’ fatigue 
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properties as well as the overall remodeling potential will also need to be evaluated using 
a bioreactor. The overall goal is to develop a TEHV for pre-clinical testing and to do so 
our TEHV must first be tested and validated under simulated aortic valve conditions using 
a pulsatile flow loop. Then, long-term performance will be evaluated through an in vivo 
sheep model, where valve integration and remodeling with the host will be studied along 
with  the hemodynamic profile of the valve. Another consideration for assessing the TEHV 
under in vivo conditions is the position in which to test the TEHV. While the objective of 
this study was to develop a TEHV for the aortic valve, it may be worthwhile investigating 
the remodeling of the TEHV under pulmonic conditions, which will be an environment 
more conducive to ECM regeneration and remodeling given the less harsh mechanical 
forces. While, the aortic valve position will evaluate the durability and overall mechanical 
function under flow conditions.  
The culmination of this work will forge new paths toward patient-specific therapies for 
pediatric heart valve patients. The application of stem cells, especially iPSCs, presents a 
new source for seeding TEHVs, enabling the field to have a scalable and more accessible 
cell source. While exciting, this cell source will need to be extensively characterized to 
ensure safety and efficacy. Nonetheless, this is an advancement important for addressing 
the cell source. Meanwhile, the utilization of 3D bioprinting to design more representative 
scaffolds, such as the circumferential orientation of the collagen fibers, allows for more 
complexity to be introduced into the geometry and composition of the scaffolds. 3D 
printing enables scaffolds to be more representative of its biological host. The approaches 
and strategy used in this thesis have all made a positive impact towards generating a tissue 
engineered heart valve for pediatric patients. The identification of 3D printing the PCL 
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scaffold using orientation that enables this material to function under physiological 
hemodynamics is believed to be the most promising results from this work. Using this 
material as the foundation for the valve leaflet, this presents the potential to develop a 
TEHV quickly by implementing other strategies such as the in-situ tissue engineering and 
also the ability to make modifications to this layer to achieve physiologically relevant 
mechanical properties. While the use of other approaches can have broader impact, the 
ultimate goal is to use a patient-specific method to ensure better outcomes for pediatric 





Table 4 List of Antibodies and Stains. 
Antibody Supplier Catalog # Host 
CD90 BUV395 BD Biosciences 563804 Mouse 
CD44 v450 Tonbio 75-0441 Rat 
CD45 PE Tonbio 50-0459 Mouse 
CD71 APC Santa Cruz Biotechnology sc9099 Rabbit 
aSMA ABCAM ab32575 Mouse 
Vimentin Santa Cruz Biotechnology  Rabbit 
Alexa Fluor® 488 Life Technologies  Anti- Rabbit 
Alexa Fluor® 488 Life Technologies  Anti- Mouse 
    
Stain Supplier Catalog #  
DAPI Invitrogen D1306  
Rhodamine-Phalloidin Invitrogen R415  
Fluorescein-5-Maleimide  Sigma 38132  
    





Procedures for collection and processing of human dermal fibroblasts for derivation of 
iPSCs were approved by the Institutional Review Board of Emory University and 
Children’s Healthcare of Atlanta. To generate integration-free iPSC lines, human 
fibroblasts were derived from a skin biopsy of a healthy child as described previously 
[284]. The fibroblasts maintained in growth phase at passage 4 were harvested and washed 
once in PBS.  5x105 cells were re-suspended in Amaxa nucleofection solution V (Lonza) 
and Yamanaka episomal plasmids [285]: pCXLE-hOct3/4-shp53-F (Addgene number 
27077), pCXLE-hSK (Addgene number 27078), and pCXLE-hUL (Addgene number 
27080) were used for reprogramming. Episomal plasmids (1 µg each) were added to the 
cell suspension and the cells were transfected using program U-023 on a Nucleofector 
device II. Immediately following transfection, cells were re-suspended in fibroblast 
medium containing 10 µM ROCK inhibitor (Stemgent) and transferred to a 10 cm tissue 
culture dish coated with 0.5% gelatin, and medium was changed daily. At day 7 post 
transfection, 1 x 105 viable cells were seeded into one well of a 6-well plate containing 
mouse embryonic fibroblast (MEF) feeders. The next day, fibroblast medium was changed 
to MEF conditioned medium (MEF-CM) supplemented with 8 ng/ml bFGF.  At day 21 
post transfection, cells were live stained with TRA-1-60 to pick iPSC colonies. The TRA-
1-60 positive colonies were picked and transferred to the feeder cells. Colonies picked were 
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maintained on feeders for 7 days and subsequently adapted to feeder-free cultures on 
Matrigel in MEF-CM [244]. 
 
Hydrogel functionalization was performed by conjugating slow-degrading 
(GGGLGPAGGK) (LGPA) peptide (Cayman Chemical, MI) to acrylate-PEG-
succinimidyl valeric acid (ACR-PEG-SVA; Laysan Bio, Inc., AL) in 50 mM sodium 
bicarbonate buffer solution at pH 8.5 (Sigma). LGPA peptide was incorporated into the 
PEG mesh network to enable MMP-sensitive degradation [253]. ACR-PEG-SVA was 
combined with LGPA at a 1:2.2 molar ratio (ACRY-PEG-SVA: LGPA) and reacted 
overnight at room temperature under constant agitation. PEG-LGPA-PEG was then 
dialyzed with MWCO membrane 3400 against 4 L of ultrapure water for 3 days with 4-5 
water changes per day. Samples were then lyophilized into a dry powder. Conjugation was 
confirmed using MALDI-TOF. 
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Figure 28. Derivation and characterization of human iPSCs. (A) Procedure of derivation of 
iPSCs.  (B) Cell morphology showing fibroblast after day 7 and emergence of iPSC colony 
day 14 after nucleofection. (C) Live staining of stem cell marker TRA1-60 and phase-
contract images of corresponding iPSC colony at day 21. (D) Characterization of iPSCs 
adapted to feeder-free cultures by immunocytochemical analysis of TRA1-81, TRA1-60, 
SSEA-4, OCT4, NANOG, and SOX2. Alkaline phosphatase (AP) was detected after the 
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cells were incubated with AP substrate solution.  (E) Detection of β-tubulin III, α-fetal 
protein (AFP) and α-smooth muscle actin (SMA) in EB outgrowth.  Scale bar = 100 µm. 
 
 
To generate integration-free iPSC lines, human fibroblasts were transfected with episomal 
plasmids expressing 6 reprogramming factors and then replated on gelatin-coated plates 
immediately following transfection [1]. At day 7 post transfection, morphology of cells 
remained fibroblast-like (Figure 28A).  These cells were then maintained in a culture 
condition to support stem cell proliferation [1]. We observed that colonies started appearing 
7 days after the cells were onto mouse embryonic fibroblast feeders (Figure 28B).  At day 
21 post transfection, TRA1-60-positive colonies with typical pluripotent stem cell 
morphology were detected following live staining (Figure 28C). Further, individual iPSCs 
colonies were manually picked and maintained on feeders for 7 days and subsequently 
adapted to feeder-free cultures.  The 902-iPSC line had typical undifferentiated cell 
morphology and expressed surface markers of human pluripotent stem cells, SSEA-4, 
TRA1-60, and TRA1-81 (Figure 28D). These surface marker-positive cells were also 
positive for transcription factors of stem cells, NANOG, OCT4, and SOX2.  In addition, 
these cells showed positive alkaline phosphatase (AP) activities, another indicator of 
pluripotent stem cells (Figure 28D).  Next, we evaluated differentiation potential of the 
iPSC line through the formation of embryoid bodies (EB) [1].  The EB outgrowth contained 
cell types of all three germ layers as detected by the expression of β-tubulin III (ectoderm), 
α-smooth muscle actin (mesoderm), and α-fetal protein (endoderm) (Figure 28E). 
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The NMR and MALDI-TOF data confirm the conjugation of RGDS to acrylate-PEG-SVA. 
In the NMR spectra, three distinct RGDS peaks are observed at 4.5, 4.0, and 3.10 ppm 
(Figure 29). In addition, a shift in mass can be detected once RGDS is conjugated to PEG 
(Figure 30). The expected mass after conjugation is 3600 Da (acrylate-PEG-SVA) plus 433 
Da (RGDS) minus 115 Da (N-Hydroxysuccinimide; NHS leaving group), which results in 
an average mass of 3900 Da for PEG-RGDS. The mass of the conjugated PEG-RGDS was 
measured at 3956 Da. Although the mass of acrylate-PEG-SVA is supposed to be an 
average of 3400 Da, there can be batch-to-batch mass variations. The acrylate-PEG-SVA 
used here was detected to average at 3600 Da. Furthermore, MALDI-TOF was also used 
to verify conjugation of acrylate-PEG-SVA and LGPA (a slow-degrading peptide). In 
Figure 31, there are two peaks at 4250 Da and 8337 Da. The first peak corresponds to PEG 
conjugated to one LGPA peptide and the second peak is the result of PEG-LGPA-PEG 
conjugation. 
 
The phenotype of iMSCs post-encapsulation at 28 days was compared to VICs and HDFs, 
maintained in same hydrogel conditions. The amount of fluorescence for each marker was 
quantified and normalized to get the percent area of fluorescence. Based on these results, 
iMSCs express similar levels of αSMA, vimentin, and periostin compared to VICs. 
However, collagen levels were significantly higher than both VICs and HDFs, and 




Figure 29. 1H NMR spectra of acrylate-PEG-RGDS. PEG-RGDS was dissolved in DMSO 
for 1H NMR characterization. Successful conjugation was confirmed by distinct RGDS 





Figure 30. MALDI-TOF spectra of acrylate-PEG-RGDS. PEG-RGDS was dissolved into 
water and mixed at a 1:1 ratio with matrix a-cyano-4-hydroxycinnamic acid. A linear 
negative mode data acquisition mode was used with a mass range of 2,000 to 10,000. A 







Figure 31. MALDI-TOF spectra of acrylate-PEG-LGPA-PEG-acrylate. PEG-LGPA-PEG 
was dissolved into water and mixed at a 1:1 ratio with matrix a-cyano-4-hydroxycinnamic 
acid. A linear negative mode data acquisition mode was used with a mass range of 2,000 
to 10,000. There are two peaks present, one at 4200 and the other at 8300 Daltons. This 
corresponds to PEG-LGPA and PEG-LGPA-PEG polymer.     
 
All three cell types, iMSCs, VICs, and HDFs, were encapsulated in 5% PEG-LGPA-PEG 
hydrogels with 5 mM RGDS. This hydrogel has a slow-degrading peptide sequence 
(LGPA), which is degraded by cells through MMP-secretion [253]. In Figure 33, there is a 




HDFs undergo demonstrated a decrease in αSMA expression. VICs have higher levels of 
vimentin expression at day 28, while no expression of vimentin was detected in hydrogels 
with iMSCs and HDFs. Interestingly, large cell aggregates were observed only in the iMSC 
group after 14 days. In Figure 34, both controls, VICs and HDFs, had observed collagen 
secretion after 28 days of encapsulation. However, iMSCs had minimal staining for 
collagen type I and, again, formed large cell aggregates. Furthermore, iMSCs maintained 
periostin expression throughout all time points similar to VICs and had minimal expression 
of calponin. Meanwhile, HDFs experienced a decrease in periostin expression as shown in 
Figure 35.  
 
Compression testing demonstrated the average modulus of degradable PEG hydrogels at 
1-minute white-light exposure to be 8 kPa. While, when cells were encapsulated into 
degradable PEG hydrogels, the modulus increased significantly to 11.8 kPa, and after 28 
days of encapsulation, there was a significant decrease in the average modulus to 5.2 kPa. 
It is worthwhile mentioning that the modulus after 28 days of encapsulation was 
significantly higher than non-degrading PEGDA hydrogels (Figure 36B). Cells could 
potentially remodel the degradable ECM more readily compared to non-degrading PEGDA 





Figure 32. iMSC phenotype comparison to VICs and HDFs after 28 days of encapsulation. 
The amount of collagen,  aSMA, vimentin, periostin, and calponin was quantified using 
fluorescent images.  The expression of each marker was compared between cell types after 
28 days of encapsulation in non-degrading PEGDA hydrogels. Significance was 
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determined comparing to iMSCs using One-way ANOVA with post-hoc Tukey-Kramer 
test. *p<0.05; ***p<0.001. N = 4-8. 
 
Figure 33. Alpha-smooth muscle and vimentin expression in cell-laden degradable 
PEGDA hydrogels. iMSCs, VICs, and HDFs were encapsulated into 5% w/v PEG-LGPA-
PEG hydrogels with 5 mM RGDS for 1, 14, and 28 days. αSMA. There is a maintained 
level of αSMA expression can be observed with iMSCs. Meanwhile, VICs and HDFs 
undergo a decrease in αSMA expression. VICs have higher levels of vimentin expression 
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at day 28, while no expression of vimentin is observed for HDFs. DAPI=Blue; Vimentin= 
Green; αSMA = Red. Scale bar 50 μm. N = 3. 
 
Figure 34. Collagen expression in cell-laden degradable PEGDA hydrogels. iMSCs, VICs, 
and HDFs were encapsulated into 5% w/v PEG-LGPA-PEG hydrogels with 5 mM RGDS 
for 1, 14, and 28 days. Both controls, VICs and HDFs, had observed collagen secretion 
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after 28 days of encapsulation. However, iMSCs had minimal staining for collagen type I. 
DAPI = Blue. Cell membrane = Green. Collagen type I= Red. Scale bar 50 μm. N = 3. 
 
Figure 35. Periostin and calponin expression in cell-laden degradable PEGDA hydrogels. 
iMSCs, VICs, and HDFs were encapsulated into 5% w/v PEG-LGPA-PEG hydrogels with 
5 mM RGDS for 1,14, and 28 days. iMSCs maintained periostin expression throughout all 
time points similar to VICs and had minimal expression of calponin. Meanwhile, HDFs 
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experienced a decrease in periostin expression. DAPI=Blue; Periostin= Green; Calponin = 
Red. Scale bar 50 μm. N = 3. 
 
 
Figure 36. Mechanical properties of degradable PEG hydrogels. A) Compression testing 
was used to determine the bulk modulus of 5% v/w PEG-LGPA-PEG hydrogels with 5mM 
RGDS, crosslinked with white-light for 1-minute. The elastic modulus in PEGDA only 
hydrogels was an average of 8 kPa. While cell-laden PEGDA hydrogels had a modulus of 
11.8 kPa, which decreased to 5.2 kPa after 28 days. B) A comparison of moduli after 28 
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days of encapsulation between non-degradable PEGDA and degradable PEG hydrogels.  





Figure 37. PCL Degradation. Scaffolds were characterized through changes in thickness 
and weight over an 8-month period. The thickness and weight were measured and 





The rheological properties of GelMA/PEGDa bioink was evaluated over 28 days. In Figure 
38, the storage and loss modulus for blank and cell-laden hydrogel was evaluated. There 
was no statistical difference among the time points.  
 
Figure 38. Rheological characterization. Frequency sweeps of storage moduli and loss 
moduli of blank GelMA + PEGDA hydrogels and GelMA + PEGDA hydrogels with 
encapsulated cells over 28 days measured by rheology. Two-way ANOVA, ** p < 0.001, 
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